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Erika deWyllie Billick, Ph.D. 
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To define pathologic alterations, a reference of "normal" cells is needed in order to 
interpret genomic methods that study gene expression of melanocytes and keratinocytes in 
growth-activated or neoplastic skin diseases.  Historically, mRNAs isolated from cultured 
epidermal keratinocytes or melanocytes are used to define normal gene expression patterns.  
In this study, we profiled global gene expression in human epidermal keratinocytes on 
Affymetrix U133 plus 2.0 arrays from three different "normal" sources: 1) cultured 
keratinocytes, 2) FACS keratinocytes from dispase-separated epidermis, and 3) laser-capture 
microdissected (LCM) epidermis.  For melanocytes, the precursor cell of melanoma, the 
attempt was made to isolate a more physiologically relevant sample source than that of the 
forced in vitro proliferating phenotype.  Our results suggested that the best definition of 
"normal" keratinocyte gene expression is obtained via LCM of normal epidermis.  Even 
short-term suspension culture of KCs (used for FACS) altered gene expression.  Established 
primary KCs in culture express some genes, e.g., keratin 16, at levels found in pathologic 
states such as psoriasis.  Currently limited by LCM methodology, the identification of 
melanocyte was defined by c-kit+ FACS samples, using the caveats of this technique 
acknowledged in the keratinocyte comparison.  The results of the gene expression analysis 
show a modulation of many important keratinocyte genes based on whether and how long 
they were in culture.  Overall, our results indicate the need to carefully consider "normal" in 
situ sources of cells in order to properly define normal vs. pathologic gene expression.   
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Materials and Methods 
 
Primary cell cultures 
 Commercially available normal human epidermal melanocytes 
(PromoCell C-12453 NHEM) were initially isolated from different locations from the 
epidermis of adult skin, including the face, the breasts, the abdomen, and the thighs. 
Melanocytes had been isolated using serum-free, phorbol myristate acetate (PMA) free 
melanocyte growth medium M2.  Since PMA is a tumor promoting mitogen that can 
interfere with experimental approaches, we used cells isolated in melanocyte growth 
medium M2 and continued to use this medium for cultivation.   After isolation, all 
PromoCell normal human epidermal melanocytes were cryopreserved at passage 2 (P2) 
by using PromoCell’s proprietary, serum-free freezing medium, Cryo-SFM.  Each 
cryovial contained more than 500,000 viable cells after thawing.  Proliferating cell 
cultures were made from 500,000 cryopreserved cells that had been thawed and cultured 
for three days at PromoCell.  Quality control tests were performed for each lot of 
PromoCell normal human epidermal melanocytes, including cell morphology, adherence 
rate, and cell viability. Furthermore, immunohistochemical tests for the cell-type specific 
marker, Mel-5 (tyrosinase), were carried out for each lot.  Growth performance was 
tested through multiple passages up to 15 population doublings (PD) under culture 
conditions without antibiotics and antimycotics.  In addition, all cells were tested for the 
absence of HIV-1, HBV, HCV, and microbial contaminants (fungi, bacteria, and 
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mycoplasma). Arrays were performed on 10 independently derived isolates of 
melanocytes.  Values reported are means for all cell strains analyzed. 
Normal human epidermal keratinocytes (NHEK) were initially isolated by 
PromoCell from the epidermis of adult skin [from different locations like the face, the 
breasts, the abdomen, and the thighs.]  C-12004 cells were tested for cell morphology, 
adherence rate, and cell viability.  Furthermore, immunohistochemical tests for the cell-
type specific marker cytokeratin were carried out for each lot.  >500,000 “passage 2” 
normal human epidermal keratinocytes (NHEK) from n=10 adult donors were purchased 
from PromoCell GmbH. Cells were equilibrated at 37°C and 5% CO2.  Grown in 
PromoCell Keratinocyte Growth Medium 2 (C-20111.)  At less than 80% confluency 
cells were washed with Dulbecco’s PBS and lysed in Qiagen RNeasy buffer RLT.  
Lysates were stored at -80°C before RNA was purified using Qiagen’s RNeasy Mini Kit.  
RNA yield was high from in vitro samples, which, were double amplified in the same 
manner as the in vivo LCM samples to reduce technical error resulting from the different 
protocol of single amplification (H. Mitsui, personal communication.)  Arrays were 
performed on 10 independently derived isolates of keratinocytes.  Values reported are 
means for all cell strains analyzed. 
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Melanocyte defined media 
Using a basal media supplemented only with insulin and hydrocortisone, cell 
morphology and survival was assessed by microscopy with all possible [individual and 
synergistic] additions of growth factors: single, double, triple and all four growth factors 
were compared to PromoCell commercial melanocyte M2 media as ‘basal’ medium [by 
using only HC and insulin supplements].  One mg of ET-3 (aSpec, cat # 24524) was 
diluted in 10 mL of PBS and aliquoted into 39 Eppendorf tubes of 250 µL at 100 µg/mL; 
the final concentration in media was 10nM.  25 µg of bFGF basic (R&D Systems, Cat# 
233-FB/CF) was re-suspended in 250 µL of PBS with 1% BSA/HAS, aliquoted into 25 
vials of 10µL, each containing 1 µg of basic FGF at a concentration of 100µg/mL for an 
end concentration in media of 10ng/mL.  5 µg human HGH (R&D Systems Cat# 294-
HGN/CF) was suspended in 250 µL of PBS with 1% BSA/HAS to make 5 10µL aliquots 
of 100µg/mL for an end concentration in media of 40ng/mL.  50 µg of SCF (R&D 
systems, Cat#255-SC/CF) was re-suspended in 1 mL of PBS and aliquoted into 5 tubes of 
200µL (containing 10µg of SCF at 50 µg/mL) the working medium concentration was 
200 ng/mL.  All growth factors once re-suspended were stored at -20°C.   
 
RNA extraction and analysis 
Lysates were kept at -80°C until samples from the same patient could be pooled 
for RNA extraction by the RNeasy Micro Kit (Qiagen Valencia, CA) according to 
manufacturer’s protocol with on-column DNase digestion.  The amount of RNA was too 
low to be analyzed by spectroscopy so the quantity was assessed using RT-PCR and a 
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standard curve created by Hiroshi Mitsui, M.D., Ph.D (personal communication.) Total 
RNA was extracted into 10.0μl of RNase free water using RNeasy Micro Kit. 
Quantitative RT-PCR (qRT-PCR) for human acidic ribosomal protein (hARP) was 
performed using the EZ PCR Core Reagent (Applied Biosystems, Foster City, CA) to 
calculate the concentration of RNA. Briefly, 1μl of total RNA was diluted into 2 μ l of 
RNase-free water. One μl of diluted total RNA was applied into a well with 49μl of RT-
PCR reaction buffer including 3 ul of primers and probe mix. Serial dilutions of total 
RNA (ranging from 2000 pg/μl to 1 pg/μl) extracted were prepared and used to make a 
standard curve.  The samples were amplified and quantified by using the 7900HT Fast 
Real-Time PCR System (Applied Biosystems) and the following thermal cycler 
conditions: 2 minutes at 50°C; 30 minutes at 60°C; 5 minutes at 95°C; and 45 cycles of 
15 seconds at 95°C followed by 60 seconds at 62°C. Assays were performed in triplicate. 
Quality of extracted RNA was then examined using Agilent Bioanalyzer 2100 (Agilent 
Technologies, Palo Alto, CA).   Amplification was performed according to the Affimetrix 
protocol for a two-cycle cDNA synthesis. We made a slight modification on two-cycle 
cDNA synthesis based on a previous report[1]. First, we used SuperScriptIII (Invitrogen, 
Carlsbad, CA) instead of SuperScriptII. Second, the total RNA/T7-oligo(dT) mix was 
incubated at 65°C for five minutes, followed by incubation for one hour at 50°C for first-
cycle, first strand cDNA synthesis. In the second cycle, non-labeled cRNA was incubated 
with Random Primers for 5 minutes at 65°C and SuperScriptIII was used to synthesize 
first-strand cDNA for one hour at 50°C. Biotin labeling of cRNA transcripts with was 
performed by using the GeneChip IVT Labeling Kit (Affymetrix).  15 µg of biotin-
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labeled RNA were fragmented and hybridized to Human Genome U133 Plus 2.0 arrays 
(Affymetrix), washed, stained, and scanned according to manufacturer’s protocol.  
 
FACS 
 We used whole tissue: peri-tumoral non-lesional skin which would otherwise be 
discarded as medical waste after Mohs’ surgery.  Subcutaneous fat was excised and 
discarded, and the remaining tissues were washed twice with PBS.  The dermal layers 
were heavily scored with a scalpel and digested in 2.4 U/mL Dispase II (Roche 
Diagnostics) overnight at 4°C. Epidermis and dermis were separated with forceps.  We 
modified the method originally reported in 1983 [2], which retrieved over 95% viable 
keratinocytes as determined by trypan blue staining.  Epidermal sheets were subsequently 
cut in small pieces and incubated with 0.25% trypsin (Invitrogen) for 10 min at 37°C.  
After washing, epidermal fragments were incubated in complete media consisting of 
RPMI 1640 (Invitrogen) supplemented with 5% pooled human serum (Mediatech), 0.1% 
gentamicin (Invitrogen), and 1% 1 M Hepes buffer (Sigma Aldrich) overnight 
(approximately 16-18 hours) at 37°C.  As even one hour of dispase abolished detection of 
many extracellular proteins [3] and trypsin cleaves exposed peptides, it was necessary to 
give the cells time (~16 hours) to regenerate their cell surface antigens.  Afterwards, a 
single cell suspension was obtained by filtration through 40 µm pore nylon cell strainers 
(BD Biosciences.)  Single cell suspensions from the epidermis were stained with the 
following mouse anti-human monoclonal antibodies: HLA-DR-Alexa Fluor 700 (IgG2a 
clone L243; BioLegend at the dilution of 1:1,000), CD207-Phycoerythrin (IgG1 clone 
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DCGM4; Immunotech at the dilution of 1:100), and CD117-Allophycocyanin (IgG1 
clone YB5.B8; BD Biosciences at the dilution of 1:100) and sorted on a FACSAria.  
Appropriate isotype controls were used.  Populations of melanocytes were collected by 
sorting CD-117+ (c-kit+) cells and populations of Langerhans cells were collected by 
sorting for HLA-DR+CD207+ cells.  The isolated HLA-DR-CD207-CD117- cell 
populations of keratinocytes, collected from a significant number of patients (n=10), were 
lysed for RNA extraction which was then amplified and hybridized to Affymetrix chips. 
 
LCM 
Laser capture microdissection (LCM) of normal human skin was performed on 10 
patients samples with Rockefeller University’s IRB consent.  Samples were frozen in 
OTC medium (Sakura) and stored at -80° before and after being cut into 8µm sections in 
a -20℃ cryostat. Two or three sections of skin were mounted on each membrane 
mounted metal frame slide (Molecular Machines and Industries, Haslett, MI), then stored 
at -80℃.  Five such slides were used to acquire enough starting material for further 
analysis.  An abbreviated Hematoxylin & Eosin (H&E) staining technique was used to 
minimize time and damage to the RNA.  LCM was performed following the 
manufacturer’s protocol for CellCut system (Molecular Machines and Industries).  The 
area of the epidermis was defined on a computer screen display and then cut by laser.  In 
the same fashion the papillary and reticular dermis were isolated.  Papillary dermis was 
completely dissected and captured separately to minimize contamination of reticular 
dermis with any epidermal components.  Special isolation cap tubes with adhesive lids 
and diffusors (from Molecular Machines and Industries) were used to capture respective 
 
 
7 
sections of epidermis, papillary dermis and reticular dermis.  The tubes were kept on ice 
until lysis by 100 μl of RLT buffer (Qiagen, Valencia, CA) and 1% β-mercaptoethanol 
(Fisher Scientific) within 2 hours from the initial staining step to minimize RNA 
degradation.  
 
Melanoma cell lines 
We collaborated with scientists in the Department of Dermatology and Allergy 
Skin Cancer Center at Charité Mitte in Berlin, Germany who had developed cell lines 
from metastatic melanoma lesions.  These cell lines are not immortalized and their 
growth in vitro varies greatly.  In fact, prior attempts to grow them in our laboratory had 
failed; only one out of six cryo-preserved vials were able to proliferate in the hands of 
very capable technicians.  In 2007, I traveled to Charité where they were able to grow 
these cell lines, also to variant degrees of success, in Dr. Uwe Trefzer’s facilities at the 
Charité-University of Medicine.  Time to confluency was mixed amongst the tumor-
derived cell lines; but in less than two weeks I was able to extract at least 19 out of 30 (T-
25 or some T-75 flasks) different tumor cell lines and lyse them [according to Qiagen’s 
protocol] in RLT + β-ME.  The samples were then shipped on dry ice to The Rockefeller 
University, where we stored them at -80℃ until which time the RNA was isolated, many 
of the cell lines that had not proliferated well (7 of the 19) did not yield enough quality 
RNA that could be used.  RNA was then amplified and hybridized to Affymetrix Plus 2.0 
gene chips as previously described. 
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Statistcal analysis 
Affymetrix CEL files were scanned for spatial artifacts by using software 
packages Harshlight [4] and arrayQualityMetrics from R/Bioconductor.  Harshlight uses 
a combination of statistic and image processing methods to identify three different types 
of defects: localized blemishes affecting a few probes, diffuse defects affecting larger 
areas, and extended defects which may invalidate an entire chip [4].  arrayQualityMetrics 
is a Bioconductor package that provides a report with diagnostic plots for one or two 
colour microarray data.  The quality metrics assess reproducibility, identify apparent 
outlier arrays and compute measures of signal-to-noise ratio. Expression values were 
obtained by using the GC-RMA (GC Robust Multi-Chip Average) algorithm.  To identify 
differentially expressed genes (DEGs), a moderated t-test was used in the limma package 
framework.  Resultant P-values were adjusted for multiple hypotheses by using the 
Benjamini-Hochberg procedure, which controls for the False Discovery Rate (FDR).  
Expression values were converted to log2 to approximate a normal distribution.    All 
through the experiments we will identify the FDR and Fold Change cut-off used to define 
the DEG lists for each table (normally log2 of 4, except for heatmaps for which fewer 
genes and a higher threshold was often used.)  Principal Components Analysis (PCA) 
was used to represent the high dimensionality of the data along the direction of maximal 
variance.  
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Chapter 1.  Introduction to the epidermis 
 
Melanoma, malignant transformation of melanocytes, is increasing now more 
than ever before.  The only cure is early detection and complete excision.  There are no 
specific chemotherapies for metastatic melanoma that have proven to increase life 
expectancy, even those currently in clinical trials targeting specific BRAF mutations in 
the patients of relevance; visually tumours seem to regress, but to no significant decrease 
in mortality.  It can therefore only be hoped that drug development will yield more 
effective treatments and that dermatologic screening can be improved upon in a disease 
that is approaching epidemic proportions; both ends depend on a better molecular 
understanding of pathology.  The majority of melanoma arise de novo; so for these 
cases it would be advantageous to be able to identify high-risk individuals on the 
genomic level.  Similarly, for melanoma that arise from congenital nevi (20-30%,) it 
would be of use to appreciate the steps of transformation. 
The majority of adults have some form of pigmented lesions.  There are many 
different types of moles or nevi, the most common being characterized by melanocytes in 
the dermis or epidermis.  Nevus & melanoma cells differ from the typical solitary 
dendritic melanocyte in that they have undergone proliferation to lie in contiguity with 
each other.  Nevi can be either benign or malignant.  It has been shown that melanoma is 
not related to the total number of nevi on any given patient, but rather the number of 
dysplastic nevi present.  It is therefore of interest to examine the molecular changes that 
accompany dysplasia and malignant transformation.  It would be extremely useful to be 
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able to identify new targets for drugs and to identify high-risk individuals on the basis of 
genomic data. 
Melanocytes are cells with dendrites that naturally touch three dozen 
keratinocytes [5].  However these cells become bipolar when grown in minimal media 
culture systems.  Under extreme conditions of starvation, such as media supplemented 
with only insulin and hydrocortisone, their cell bodies become deflated and 
morphologically spindle-shaped.  Melanocytes have co-evolved to protect the replicating 
cells from the continual exposure of the skin to the sun.  The ozone layer partially 
absorbs harmful ultraviolet light; but, in the face of persistent sun exposure and the recent 
degeneration of this atmospheric layer, the mutagenic effects correlate with an increased 
rate of skin cancer.  
The mammalian epidermis is a continually renewing structure that provides the 
interface between the organism and an innately hostile environment.  Melanin absorbs 
sunlight, thereby protecting keratinocytes from damage from UV irradition.  Melanocytes 
near the stratum basale make and export melanin through their dendrites to local 
keratinocytes.  Melanized keratinocytes are constantly shed during desquamation, 
creating a need for continual synthesis of melanin, and transfer to new keratinocytes that 
are still alive.  Adequate pigmentation of the skin is dependent on many factors within 
this unit.  Melanocytes need to receive the proper signals to synthesize melanin as well as 
the melanosomes that package, transport and transfer it from the cell body to the 
periphery of the dendrite.  Whole organelle donation from one cell to a heterologous cell 
is unique to the melanocyte-keratinocyte unit [6].  Melanophores (referred to as 
melanocytes in humans) have thousands of melanosomes compartmentalizing melanin 
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into vesicles that range from 0.3 to 1 µm.  Of neural crest origin, differentiated 
melanocytes have protrusions that radiate from the cell body that give the distinctive 
dendritic or stellate appearance.  In humans, the primary role of pigment is to protect 
against ultraviolet radiation from the sun, but may also play an important role in the 
immune system.  Mammals have two types of melanin, both synthesized from 
dopaquinone, which is a derived from oxidized tyrosine.  Humans have black/brown 
eumelanin and also red/yellow pheomelanin, unique to upper vertebrates. 
Importantly, melanocytes exist in vivo in intimate association with keratinocytes.  
The keratinocyte is the principal cell component.  Keratinocyte proteins form a physical 
epithelial barrier, protect against microbial damage, and prepare immune responses to 
danger.  In human epidermis, functional symbiosis requires homeostatic balance between 
keratinocytes and melanocytes.  Compelling evidence from co-culture studies 
demonstrated a sophisticated, multileveled regulation of normal melanocytic phenotype 
orchestrated by undifferentiated, basal-type keratinocytes.  Keratinocytes control cell 
growth and dendricity, as well as expression of melanoma-associated cell surface 
molecules of normal melanocytes.  In contrast, melanoma cells are refractory to the 
keratinocyte-mediated regulation. 
Thus in order to understand melanocyte gene expression, it is essential to consider 
keratinocyte gene expression.  In vivo, keratinocytes exist in stratified layers within the 
epidermis.  The stratum corneum (SC), the uppermost layer of the human epidermis, 
provides the vital divider between the organism and its environment.  It is generated by 
keratinocytes that migrate from the basal layer to the surface of the epidermis while 
terminally differentiating via a calcium-dependent process.  Keratins are bundled into 
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macrofibrils through their association with filaggrin, while the cornified envelope is 
being assembled and cross-linked by Ca++-dependent transglutaminase enzymes to form 
the epidermal barrier.  The final steps in keratinocyte demarcation are most pronounced 
by the alterations in cell structure and morphology.  Keratins are aligned in an ordered 
array, condensed by the matrix protein filaggrin.  Low concentrations of calcium in the 
basal layer of the epidermis favor keratinocyte proliferation, and an increasing calcium 
gradient toward the surface influences the complex delineation process.  Thus, calcium-
binding proteins, which mediate calcium signals by interacting with and modulating 
specific target proteins, are pertinent for epidermal differentiation.  
Keratins are the major gene product of keratinocytes and form the intermediate 
filament cytoskeletal network in these cells of the epidermis.  Intermediate filament 
proteins consist of a central alpha-helical rod domain flanked by non-helical sequences of 
varying size and composition.  Keratin proteins fall into two classes based of their 
electrophoretic properties and sequence similarities.  One member of each class is 
required to form the heterodimeric coiled-coil precursor, which, through lateral and 
longitudinal associations, forms the mature keratin intermediate filament.  The major 
epidermal keratins of the type I class are KRT9, KRT10, KRT14 and KRT16; the major 
epidermal keratins of the type II class are KRT1, KRT2, KRT5, KRT6A and KRT6B.  
The expression of individual keratins is both specific for the particular body site as well 
as for the exact stage of differentiation of the epidermal keratinocyte.  In addition to their 
importance for the structural integrity of the epidermis, keratin networks function in 
inter-cellular signaling.  
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Figure 1.  Diagram of the epidermis 
 
Keratinocytes in the basal layer express KRT5 and KRT14.  This layer of the 
epidermis represents the stem cell-like feature of the skin as only these cuboidal, 
columnar cells undergo continuous replication.  Upon differentiation and migration to the 
spinous layer, these keratin genes are downregulated and the expression of KRT1 and 
KRT10 is induced, and these gene products become the predominant filamentous 
network in the subsequent cellular layer.  Named because of the abundance of 
desmosomes, it is within the stratum spinosum of polygonal ‘prickle-cells’[7] where the 
process of cornification begins.  In cells of the upper spinous layer, KRT2 and KRT9 are 
expressed.  The other major epidermal keratins, KRT6 and KRT16, are normally 
expressed in the outer root sheath of the hair follicle and in palmoplantar epidermis (the 
latter was not examined in this study.)  
The stratum granulosum cells acquire keratohyaline granules that are 
predominantly filled with profilaggrin, which is the 400 kD precursor of the ~37 kD 
fillagrin peptides that aggregate keratin filaments into tight bundles that eventually lead 
to the collapse of the cell into flattened squames [8] that are anucleated and have lost 
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unnecessary organelles.  The “grainy” third layer is also the location of loricrin 
deposition.  Loricrin comprises the vast majority of the cornified envelope: 70-80% of the 
total protein mass[8].  
The corneocytes are tightly opposed to each other.  The barrier to water, though, 
is not absolute.  Transepidermal water loss (TEWL) is the normal passage of water 
through the stratum corneum into the atmosphere.  Pronounced changes in lipid 
composition accompany keratinocyte differentiation.  Lamellar granules, termed 
keratinosomes, are visible [most prominently in the granular cell layer] by transmission 
electron microscopy of the epidermis.  These membrane-bound organelles contain 
stacked lamellae composed of phospholipids, cholesterol, and glucosylceramides.  During 
transition of a granular cell into a corneocyte the keratinosome fuses with the membrane 
to release lipids and acid hydrolases that break down the phospholipids and convert 
glucosylceramide to ceramides.  The result is an equimolar mixture of ceramides, free 
fatty acids and cholesterol plus <5% [by weight] cholesterol sulfate. 
Over a decade ago, in 1996, the phrase "epidermal differentiation complex" 
(EDC) was coined in the Journal of Investigative Dermatology to describe the almost 2-
Mb locus on human chromosome 1q21 that contains at least 45 genes [9] encoding both 
epidermal cornification and S100 proteins[10].  The first family of the EDC consists of 
13 genes, including involucrin, loricrin, and 3 classes of small proline rich proteins: 2 
SPRR1 genes 8 SPRR2 genes, and 1 SPRR3 gene.  These genes encode structural 
proteins of the human epidermis, which the transglutaminase enzymes crosslink to yield 
the cornified cellular envelope.  The second family of the EDC consists of profilaggrin 
and trichohyalin.  These genes encode intermediate filament-associated proteins 
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synthesized in the granular layer of the epidermis that conjoin with the keratin filaments 
of keratinocytes during cornification.  The third family of genes in the EDC consists of 
10 genes of the S100 family, S100A1 through S100A10.  These encode small calcium- 
binding proteins with 2 EF-hands.  
For the past four decades, the study of skin has often been conducted in 
vitro where skin is supplemented with many growth factors and hormones.  Terminally 
differentiated cells like keratinocytes or even melanocytes have been grown in cultured 
media and assumed to be “normal” cells, though, these cell types are largely non-
proliferative in vivo.  In turn the predominant, in vitro characterization of a normal skin 
cell is somewhat skewed and may differ significantly from the in vivo state.  It has long 
been acknowledged that keratinocytes in culture often resemble pathogenic stages. 
In wound healing and many pathologic conditions, keratinocytes become 
activated: they turn into migratory, hyperproliferative cells that produce and secrete 
extracellular matrix components and signaling polypeptides.  At the same time, their 
cytoskeleton is also altered by the production of specific keratin proteins [11].  These 
changes are orchestrated by growth factors, chemokines, and cytokines produced by 
keratinocytes and other cutaneous cell types.  The responding intracellular signaling 
pathways activate transcription factors that regulate expression of keratin genes.  
Keratinocytes are activated by the release of IL-1.  Subsequently, they maintain the 
activated state by autocrine production of proinflammatory and proliferative signals.  
Keratins K6 and K16 are markers of the active state of regenerative maturation [11].  
Signals from the lymphocytes, in the form of interferon-gamma, induce the expression of 
K17 and make keratinocytes contractile.  This enables the keratinocytes to shrink the 
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provisional fibronectin-rich basement membrane.  Signals from the fibroblasts, in the 
form of TGF-beta, induce the expression of K5 and K14, revert the keratinocytes to the 
healthy basal phenotype, and thus complete the activation cycle. 
Keratinocytes have long been studied in culture.  For differentiation to occur upon 
reaching confluency in culture conditions, removal of exogenous growth factors is in fact 
necessary, which demonstrated their autocrine capabilities.  Keratinocytes provide 
themselves with the growth factors necessary for their proliferative phenotype.  The 
three-dimensionality of the epidermis is not recapitulated but some stratification can be 
observed.  Though grown in an artificial environment, late makers of differentiated 
keratinocytes such as loricrin, filaggrin and transglutaminase-1 are produced in addition 
to cytokeratins 10.  Keratin 14 and involucrin are detected at lower confluency.  Aside 
from studies in animals like mice, culture, however artificial, has been the norm for the 
study of keratinocytes.  Yet the physiological relevancy of in vitro experimentation has 
never been detailed by large genomic study.   
The idea that cancer develops through progressive mutations/alterations in normal 
cells is at the heart of the Vogelstein model of colon cancer pathogenesis.  In this model, 
normal colonic epithelial cells evolve to become benign proliferative neoplasms 
(adenoma) and then those lesions acquire additional alterations that convert benign 
neoplasms to malignant ones [12].  This model seems well suited for the skin in that 
keratinocyte neoplasms seem to progress from dysplastic lesions (acanthomas, actinic 
keratoses), to in situ carcinomas, to invasive carcinomas.  Likewise, melanocytes undergo 
benign proliferative conversion to nevi, and progressive dysplasia in nevi leads to 
melanomas, which also seem to progress from in situ to invasive lesions. 
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This thesis project is directed at identifying critical gene expression pathways that 
are associated with early steps in melanocyte pathology, i.e., the conversion of a stable, 
non-proliferative melanocyte within the epithelium to a proliferative phenotype.  In 
addition, there is critical cross-regulation of melanocyte growth by epidermal 
keratinocytes, which supply numerous growth factors for the melanocytes.  Keratinocytes 
are plastic in human skin in that they can exist in a low-proliferative homeostatic growth 
state (with low production of growth factors) or in a state of accelerated 
growth/differentiation called ‘regulated maturation’ where production of relevant growth 
factors is increased. 
It can be postulated that genes activated or suppressed in culture may be mutated 
in cancer.  Genes that are gained with culture are generally more interesting than those 
lost (unless they are tumor suppressors.)  In this thesis, there is thus an effort to define 
growth-activated expression pathways in both melanocyte and keratinocytes, since both 
sets of pathways may influence benign or malignant transformation.  Thus a critical 
starting point is to define the “normal” genomic profiles of keratinocytes and 
melanocytes in normal human skin before induced proliferation occurs.   
To this end we set out to study and compare the gene expression of 
keratinocytes: in vitro, ex vivo as collected by FACS and in situ by LCM.  The staining of 
human tissue for LCM greatly damages the RNA needed for analysis of gene expression.  
We are able to collect pieces of the epidermis and dermis as stained by a simple H&E 
method; but, it is currently not possible to stain melanocytes specifically for dissection.  
We compared the gene expression of melanocytes isolated by their expression of CD-
177, or c-kit, with commercial ‘normal human epidermal melanocytes’ in culture using a 
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proprietary medium sold by PromoCell.  The use of serum and other unknown elements 
(eg pituitary homogenate) affect gene expression such that typical ingredients of 
melanocyte growth media must be excluded.  The best methodology at this point to 
examine true physiological qualities of in vivo melanocytes is by FACS of epidermal cell 
suspensions and by the study of primary cultures in defined medium, which was created 
as detailed in Chapter 6.   
As a way to look at progression we analyzed cultured cells from metastatic 
melanoma tumors.  We compared the gene expression of a significant number (n=7) of 
melanoma cell lines, normal human epidermal melanocytes in vitro and the FACS 
derived melanocytes. 
This thesis therefore takes a close look at the genomics of normal keratinocytes 
and melanocytes in the attempt to determine how precisely they represent normal cells in 
vivo through a variety of techniques.  Our conclusions confirm the artifacts created by 
tissue culture and attempt to categorize the changes precisely so that all the studies 
conducted with this model system can be examined with the appropriate stipulations.  We 
also provide insight into hyperplastic and neoplastic growth amongst these two cell types 
in the epidermis.  
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Chapter 2.  Laser capture microdissection of skin 
 
Theory and aims 
Growth and differentiation are tightly linked processes in the epidermis that must 
be balanced precisely.  If there are too many dividing cells, hyperproliferative disorders 
of the skin can result (eg psoriasis, basal- or squamous-cell carcinomas.)  The epidermis 
controls this balance partly by an orchestrated transcriptional program that creates 
temporally and spatially distinct epidermal cells: each carrying out functions necessary 
for their specific position within the skin.  In the basal layer are the only cells actively 
undergoing replication.  At some point the keratinocytes will stop dividing, detach from 
the basement membrane and enter a path of terminal differentiation that will ultimately 
allow them to form the barrier necessary for the proper function of the skin.  
Keratinocytes form a three-dimensional lattice that can only be replicated in culture with 
the addition of exogenous extracellular matrix proteins to provide for the scaffolding 
necessitated by such structural complexity.  In addition cultured cells are highly 
proliferative, whereas those in normal skin are not [unless activation signals are sensed 
such as those necessary for wound healing.]  It therefore stands to reason that cultured 
cells are not an appropriate model system from which to study the epidermis at the 
molecular level. 
This chapter is based on the hypothesis that primary cells in culture, though not 
immortalized, should not be treated as ‘normal’ ex vivo representations.  In order to prove 
this idea, it was necessary to find a source of epidermal keratinocytes that had yet to be 
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isolated and influenced by exogenous culture milieu.  Using laser capture microdissection 
it was possible to isolate the epidermis (98% keratinocyte cells) directly from human 
tissue samples.  Analysis of extracted RNA expressed from cultured primary cell lines, as 
compared with the “in vivo” epidermal LCM-captured samples, showed extreme genetic 
variation from what the current ‘gold standard’ of primary normal human epidermal 
keratinocytes in vitro.  
 
Dermis versus epidermis gene sets 
In order to show the validity of LCM to detect differential gene expression in 
human skin components, the top genes expressed in the epidermal and dermal samples 
captured, and amplified through Affymetrix assays were examined.  Cut-off fold change 
(FCH) of 4 was used and a p value of 0.05; though, for the sake of brevity, 10 
representative genes were chosen for the tables in this chapter (as the Affymetrix U133 
Plus 2.0 chips detect over 47,000 transcripts.)   
Genes highly expressed in dermis include many types of collagens, as expected 
for their function in scaffolding, as well as endothelial cell products such as complement 
factors and PECAM1 (Table 1a).  Of note is CXCL12, a chemokine present here in non-
inflamed tissue; though, previously reported to be secreted by aging stromal fibroblasts 
[13].  Table 1a. columns of “Dermis” and “Epi” highlights mean log base 2 values of 
gene expression as detected on arrays (n=10) of the fold elevation in the dermis collected 
versus epidermis.   
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Table 1a.   
Genes highly expressed in normal human dermis/epidermis by Fold Change (FC) 
                   
 
Symbol Description FC log2FC P fdr Dermis Epi 
CXCL12 chemokine ligand 12  2231.8 -11.1 0 0 13.6 2.5 
C3 complement component 3 1250.2 -10.3 0 0 13.4 3.1 
CFH complement factor H 903.9 -9.8 0 0 12.5 2.6 
COL1A2 collagen, type I, alpha 2 762.2 -9.6 0 0 13.7 4.1 
COL3A1 collagen, type III, alpha 1 717.6 -9.5 0 0 12.5 3.0 
COL6A3 collagen, type VI, alpha 3 775.0 -9.6 0 0 13.1 3.5 
PECAM1 
platelet/endothelial cell 
adhesion molecule 721.6 -9.5 0 0 13.0 3.5 
FBN1 fibrillin 1 466.9 -8.9 0 0 12.7 3.8 
PDGFRA 
platelet-derived growth factor 
receptor, alpha  429.3 -8.7 0 0 12.5 3.8 
VCAN versican 426.4 -8.7 0 0 11.5 2.8 
 
Conversely, the genes expressed most highly in the epidermis (Table 1b) play a 
large role in maintaining the strength and integrity of epithelial tissue, including several 
members of the EDC.  Marenholz et al. (1996) noted that calcium levels tightly control 
epidermal differentiation and expression of EDC genes [17].  Due to the importance of 
calcium in the regulation of keratinocyte differentiation, it is rational to expect to see 
certain Ca++ binding protein in the epidermis.  Accordingly, calmodulin-like skin protein 
(CLSP) was highly differentially expressed in the epidermal list.  The high expression 
levels of the late cornified envelope 1B gene (LCE1B) and the keratinocyte 
differentiation-associated protein (KRTDAP) are perhaps the most obvious tissue-
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specific markers of the epidermis, as they are keratinocyte products that would not be 
expressed in dermal tissue.   
Table 1b. highlights the columns designated “Dermis” and “Epi” represent mean 
ln values of gene expression as detected on arrays (n=10) of the fold elevation in the 
epidermis collected versus dermis.  Cut-off fold change (FCH) of 4 was used with a p 
value of 0.05. 
 
Table 1b.   
Genes highly expressed in normal human epidermis/dermis by Fold Change (FC) 
Symbol Description 
Fold 
elevation 
in 
epidermis log2FC P fdr Dermis Epi 
DSC1 desmocollin 1 647.679 9.3 0 0 3.7 13.1 
DSG1 desmoglein 1 620.481 9.3 0 0 3.8 13.1 
KRT2 keratin 2 479.378 8.9 0 0 5.4 14.3 
CALML5 calmodulin-like 5 420.781 8.7 0 0 3.1 11.8 
LCE1B late cornified envelope 1B 358.767 8.5 0 0 5.2 13.7 
SBSN suprabasin 343.175 8.4 0 0 5.2 13.6 
PKP1 
plakophilin 1 (ectodermal 
dysplasia/skin fragility) 320.515 8.3 0 0 4.0 12.3 
KRTDAP 
keratinocyte differentiation-
associated protein 298.7 8.2 0 0 6.4 14.7 
LOR loricrin 297.698 8.2 0 0 5.3 13.5 
CST6 cystatin E/M 279.39 8.1 0 0 3.2 11.3 
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Keratin 2, of the spinous layer is highly expressed in the “in vivo” epidermis 
collected by LCM as opposed to the dermis.  Suprabasin has been identified as an 
epidermal differentiation marker and potential cornified envelope precursor, expressed 
only in the suprabasal layers of epidermis with differentiating keratinocytes [14].  
Loricrin is a major component of the crosslinked cell envelope of the epidermis, 
otherwise known as cornified cell envelope (CE), marginal, or peripheral band.  Cystatin 
M/E has a restricted expression pattern in humans largely limited to cutaneous epithelia 
[15,16].  It has also been suggested that cystatin M/E is required for viability and for 
correct formation of cornified layers in the epidermis and hair follicles.  
There are many unique ectodermal cell:cell junctional proteins that make up the 
desmosomes in the epidermis, such as desmoglein and desmocollin.  Another 
desmosomal component is plakophilin, also expressed at high levels in the epidermis.  
The detectable expression of these molecules is consistent with an isolated epidermis, 
confirming the LCM methodology.   
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In vivo versus in vitro primary keratinocytes 
After we were confident that we had correctly dissected the epidermis, we were 
then able to compare its gene expression to that of ‘primary’ keratinocytes growing in 
vitro.  It is important to note that in vitro keratinocytes grown in culture do go through 
stages of differentiation, though, they appear to differ from in vivo stages of 
differentiation.  For example, in vitro keratinocytes have been shown to express wound 
healing and psoriatic markers [11] which suggest alternative genomic circuits at play.  In 
this evaluation we can consider the varying levels of cytokines and growth factors (both 
paracrine and autocrine) as well as their receptors, cell cycle and epidermal 
differentiation complex genes expressed in vitro in normal human epidermal 
keratinocytes (NHEK) which have been considered the norm for the past several decades.   
 
Epidermal differentiation complex (EDC) and related genes of the epidermal barrier 
 Though the EDC is strictly defined as genes in one locus on the same 
chromosome, some relevant genes from other loci are included in this analysis as many 
of the EDC genes may not be expressed in vitro.  Table 2a. highlights the mean fold 
elevation (FC) in vitro (n=10) as compared to the LCM epidermis (n=10).  
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Table 2a.  Genes up-regulated in vitro [as compared to LCM] 
Symbol Description FC log2FC P fdr in vitro LCM 
PI3 
peptidase inhibitor 3,        
skin-derived 85.3 6.42 0 0 10.15 3.74 
S100A6 
S100 calcium         
binding protein A6 29.0 4.86 0 0 12.84 7.98 
ACER3 alkaline ceramidase 3 16.2 4.02 0 0 8.69 4.68 
ACSL3 
acyl-CoA synthetase        
long-chain family 3 14.9 3.90 0 0 12.01 8.12 
ACSL4 
acyl-CoA synthetase        
long-chain family 4 13.1 3.71 0 0 8.10 4.39 
SPRR1B 
small proline-rich   
protein 1B (cornifin) 7.5 2.91 0 0 14.63 11.73 
SCARB1 
scavenger receptor  
class B, member 1 6.1 2.60 0 0 9.78 7.18 
ST3GAL5 
ST3 beta-galactoside α-
2,3-sialyltransferase 5 5.8 2.53 0 0 8.44 5.92 
TGM1 
transglutaminase 1     
(K epidermal type I) 4.7 2.23 0 0 11.03 8.80 
SPRR4 
small proline-rich 
protein 4 4.4 2.15 0 0 4.67 2.52 
 
PI3, or SKALP, peptidase inhibitor 3 has been identified in psoriatic patient skin 
but is absent in normal human epidermis.  It is therefore of interest that it was expressed 
at extremely high levels in culture as compared to LCM epidermis [18].  Expression of 
S100A6, a member of the S100 calcium binding proteins that typically regulate the 
epidermis, has been documented in a variety of human cancer tissues [19] and is diffusely 
expressed in Spitz nevi and in melanoma to a lesser extent [20].  The exact function of 
ST3GAL5 remains to be elucidated, other than its role in the sphingolipid metabolism 
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that has been implicated in cellular cross-talk in cell survival and resistance to 
apoptosis[21].  EDC gene SPRR1B has been reported to quench reactive oxygen species 
in wound healing [22].  SPRR4 was only recently identified as a cornified envelope 
precursor, due to its low expression levels in vivo, induced by UV light and concomitant 
thickening of the stratum corneum [23].  Transglutaminase 1 expression in vitro was 
increased, probably because it is produced primarily by keratinocytes [8] and there are 
many transglutaminases present in skin creating somewhat of a functional redundancy. 
The epidermis is an active site of cholesterol synthesis.  SCARB1, up-regulated 6-
fold in vitro, has been reported to be at its greatest expression level in undifferentiated 
keratinocytes [24].  Altered expression of lipid metabolism is also seen in keratinocytes 
in vitro which goes along with the down-regulation of EDC the gene expression [as seen 
in Table 2b.]  ACSL3 and ACSL4 were both up-regulated in culture relative to in vivo 
epidermis.  The proteins encoded by these gene are isozymes of the long-chain fatty-acid-
coenzyme A ligase family.  Although differing in substrate specificity, subcellular 
localization, and tissue distribution, all isozymes of this family convert free long-chain 
fatty acids into fatty acyl-CoA esters, and thereby play a key role in lipid biosynthesis 
and fatty acid degradation.  The ACSL3 isozyme is highly expressed in brain, and 
preferentially utilizes myristate, arachidonate, and eicosapentaenoate as substrates.  The 
ACSL4 isozyme preferentially utilizes arachidonate as substrate.  It is unusual to see 
these isozymes expressed in keratinocytes as there have been no other such reports; and, 
arachidonate is not the usual substrate in the human epidermis. 
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Table 2b.   Epidermal barrier genes up-regulated in LCM [as compared to in vitro] 
Symbol Description FC log2FC P fdr in vitro LCM 
LOR loricrin 231 -7.851 0 0 6.37 14.22 
CD1A CD1a molecule 57 -5.84 0 0 2.27 8.11 
LCE2B late cornified envelope 2B 25 -4.651 0 0 6.04 10.69 
CLDN23 claudin 23 24 -4.609 0 0 4.07 8.68 
FLG filaggrin 23 -4.509 0 0 9.83 14.34 
SCEL sciellin 16 -3.98 0 0 8.09 12.07 
LCE1B late cornified envelope 1B 15 -3.863 0 0 10.11 13.97 
NSMAF 
neutral sphingomyelinase 
activation factor 11 -3.465 0 0 3.16 6.62 
CDSN Corneodesmosin 8 -2.962 0 0 7.94 10.90 
EVPL Envoplakin 5 -2.335 0 0 7.87 10.20 
 
  Loricrin, upregulated 231-fold in the epidermis as compared to in culture, appears 
initially in the granular layer of human epidermis and forms composite keratohyalin 
granules with profilaggrin (upregulated 23-fold); along with involucrin it is a major 
component of the crosslinked cell envelope (CE) of the epidermis.  Late cornified 
envelope proteins 1B and 2B were expressed 15- and 25-fold higher in the epidermis, 
respectively.  Sciellin, a component of the CE, was also relatively upregulated in LCM.  
NSMAF is a crucial component of epidermal barrier repair [25].  Corneodesmosome is 
unique to anucleated corneocytes, and along with enveloplakin, and claudin 23 have roles 
in cell adhesion; these molecules were all relatively highly expressed in epidermis as 
compared to the lateral keratinocyte structures seen in culture.   
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CD1a is a Langerhans cell marker, expressed in the epidermis but detected at low 
levels in keratinocyte cultures.  This is just a caveat of LCM of the epidermis, it is not a 
pure keratinocyte population, and contains a small number of Langerhans cells as well as 
melanocytes.  Further discussion of the benefits and drawbacks of methodology can be 
found in Chapter 3. 
 
 
Growth factors, cytokines/chemokines and their receptors  
The differential expression of growth factors, cytokines, chemokines and their 
receptors is perhaps the most obvious testimony of how differently the cells in variant 
surroundings are being operated with regards to genomic circuitry.  In vivo LCM samples 
show high expression of a variety of chemokine receptors indicating cellular response to 
the immune components of the natural environment of the skin (Table 4a.)  Cells grown 
in vitro on the other hand show more hormone and growth factor receptors exogenous to 
the normal human milieu, with more of a response to elements in the growth media.  A 
set of representative gene is shown on the next page in Tables 3a and 3b with a log2 fold 
elevation cut-off in vitro of 4 and p value less than 0.01. 
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Table 3a.  
Growth factors and chemokines up-regulated in vitro [as compared to LCM] 
Symbol Description FC log2FC P fdr in vitro LCM 
AREG amphiregulin 862 9.752 0 0 13.96 4.21 
IL1A interleukin 1, alpha 383 8.58 0 0 11.07 2.49 
VEGFC 
vascular endothelial growth 
factor C 216 7.758 0 0 10.03 2.27 
IL1B interleukin 1, beta 98 6.621 0 0 9.58 2.96 
CXCL1 
GRO alpha (melanoma 
growth stimulating activity, 
alpha) 37 5.212 0 0 8.11 2.89 
IL8 interleukin 8 36 5.18 0 0 7.56 2.38 
PXN paxillin 27 4.744 0 0 9.46 4.72 
SOCS2 
suppressor of cytokine 
signaling 2 21 4.418 0 0 7.85 3.44 
HBEGF 
heparin-binding EGF-like 
growth factor 21 4.4 0 0 9.10 4.70 
STAT3 
signal transducer and 
activator of transcription 3  14 3.765 0 0 7.35 3.59 
PDGFC 
platelet derived growth 
factor C 6 2.609 0 0 10.88 8.27 
IRS1 insulin receptor substrate 1 5 2.281 0 0 6.14 3.86 
GRB10 
growth factor receptor-
bound protein 10 5 2.191 0 0 5.32 3.13 
NRP1 neuropilin 1 4 2.074 0 0 5.74 3.66 
VEGFA 
vascular endothelial growth 
factor A 4 2.064 0 0 8.36 6.29 
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Table 3b.  Growth factor and chemokine receptors up-regulated in vitro  
     [compared to LCM epidermis] p<0.01 Fold change (FC)>4 
Symbol Description FC log2FC P fdr 
in 
vitro 
LCM 
Epi 
TNFRSF21 
tumor necrosis factor receptor 
superfamily, member 21 182 7.51 0 0 11.05 3.54 
NR2F2 
nuclear receptor subfamily 2, 
group F, member 2 84 6.39 0 0 9.63 3.24 
TNFRSF12A 
tumor necrosis factor receptor 
superfamily, member 12A 54 5.77 0 0 10.85 5.08 
TNFRSF10B 
tumor necrosis factor receptor 
superfamily, member 10b 24 4.61 0 0 12.58 7.97 
FOLR3 folate receptor 3 (gamma) 22 4.48 0 0 7.58 3.09 
GRB10 
growth factor receptor-bound 
protein 10 16 4.04 0 0 8.79 4.75 
IL4R interleukin 4 receptor 15 3.90 0 0 10.20 6.30 
TRAF4 TNF receptor-associated factor 4 14 3.77 0 0 6.32 2.55 
 
The mammalian members of the epidermal growth factor (EGF) family of growth 
factors include EGF itself, transforming growth factor-alpha (TGFA) amphiregulin 
(AREG) heregulin (HGL) and betacellulin (BTC).  These act as autocrine & paracrine 
factors. AREG is an autocrine factor for keratinocytes and is expressed at increased levels 
in psoriatic epidermis.  It is also has been shown that AREG enhances protection against 
nematodes in a mouse model and was expression was increased in parallel with typical 
Th2 cytokines.  In keratinocytes grown in vitro AREG is up almost 3 logs (base 10) 
compared to expression levels in LCM in vivo samples [26].  It is therefore of interest 
that Th2 cytokine receptors IL4R, IL13RA1 and IL13RA2 are also both increased in vitro 
along with heparin-binding EGF-like growth factor (HBEGF.) 
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 The insulin-like growth factor 1 receptor (IGF1R) plays a critical role in 
transformation events.  It is highly over-expressed in most malignant tissues where it 
functions as an anti-apoptotic agent by enhancing cell survival.  The p53 gene, the most 
frequently mutated gene in human cancer, is a nuclear transcription factor that blocks cell 
cycle progression and induces apoptosis.  Werner et al. (1996) reported results of 
experiments that indicated that mutant p53 proteins have a stimulatory effect on promoter 
activity, whereas wildtype p53 suppresses the activity of the IGF1R promoter [27].  
These effects of p53 seemed to involve its interaction with components of the basal 
transcription machinery.  Due to the central role of IGF1R in cell cycle progression and 
transformation, derepression of IGF1R promoter by mutant p53 may constitute an 
important paradigm in tumorigenesis. (Most of the cancer-related mutations of p53 occur 
in the central domain of the p53 molecule.)  SOCS2 negatively regulates cytokine 
receptor signaling via the Janus kinase /signal transducer and activation of transcription 
pathway (the JAK/STAT pathway) [28].  It interacts with IGF1R and thus may play a 
regulatory role in IGF1 receptor signaling. 
Many polypeptide mitogens, such as basic fibroblast growth factor (FGFB) and 
platelet-derived growth factors are active on a wide range of different cell types. In 
contrast, vascular endothelial growth factor (VEGF) is a mitogen primarily for vascular 
endothelial cells.  It is, however, structurally related to platelet-derived growth factor.  
Platelet-derived growth factors, such as PDGFC, trigger mitosis and entry into the cell 
cycle.  Frantz et al. (1997) found that, upon insulin stimulation, the 65-kD form of 
GRB10 translocated from the cytosol to the membrane [29].  GRB10 also bound 
activated platelet-derived growth factor receptor (PDGFRB) and epidermal growth factor 
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receptor, suggesting that GRB10 functions downstream from activated insulin and 
growth factor receptors.  PDGFC, VEGFA, VEFGC and GRB10 are all up-regulated in 
culture relative to LCM.  VEGF overexpression by basal keratinocytes has been reported 
in psoriasis [30], therefore, suggesting a hyperplastic state of keratinocytes in vitro. 
STAT3 is activated by a variety of cytokines and growth factors such as 
interleukin-6, epidermal growth factor (EGF), hepatocyte growth factor (HGF), platelet-
derived growth factor, and granulocyte colony-stimulating factor.  STAT3 also regulates 
the phosphorylation of paxillin (PXN), upregulated here in culture, known to affect cell 
migration.  Focal adhesion kinase (p125FAK) is a cytosolic kinase that is concentrated in 
focal contacts[31].  Due to its localization, p125FAK has been thought to be involved in 
regulating cell morphology and cell migration in response to cell adhesion to extracellular 
matrix proteins. p125FAK is rapidly phosphorylated following cell attachment to 
fibronectin-coated surfaces or integrin clustering by antibodies.  p125FAK is also 
considered a focal adhesion docking protein capable of facilitating the recruitment and 
activation of other tyrosine-phosphorylated signaling molecules, such as pp60src and 
paxillin.  Paxillin is another signaling molecule that localizes to focal adhesions and 
becomes tyrosine phosphorylated either during integrin-mediated or growth factor-
induced adhesion; and, is highly upregulated in culture conditions.  Paxillin contains a 
domain that interacts with the C-terminus of p125FAK, and p125FAK recruitment to focal 
contacts appears to require paxillin binding.  Paxillin has been demonstrated to be a 
substrate for p125FAK phosphorylation in both in vitro [32] and in vivo systems [33,34]. 
Recently, treatment with several peptide hormones such as prolactin, insulin-like growth 
factor I (IGF-I), hepatocyte growth factor, vascular endothelial growth factor, and 
 
 
33 
platelet-derived growth factor (PDGF) have been shown to augment the tyrosine 
phosphorylation of p125FAK, the paxillin-MAPK complex serves as a central regulator of 
HGF-stimulated focal adhesion kinase and Rac activation in the vicinity of focal 
adhesions, thus promoting the rapid focal adhesion turnover and lamellipodia extension 
that are required for migratory and tubulogenic responses [35].  
Oncostatin M (OSM) is a member of the IL6 family of cytokines.  Functional 
receptors for IL6 family cytokines are multisubunit complexes involving members of the 
hematopoietin receptor superfamily.  Many IL6 cytokines utilize gp130 (IL6ST) as a 
common receptor subunit.  OSM binds to the gp130 receptor subunit and, in association 
with leukemia inhibitory factor receptor (LIFR), induces a proliferative response in 
permissive cells.  OSMR expression was upregulated with lipopolysaccharide (LPS) 
treatment.  
Several genes highly expressed in vitro are known associates of cancers.  Levels 
of cell membrane-associated folate receptors (FOLR) are elevated in a variety of 
malignant tissues compared to their normal counterparts.  Using PCR, Shen et al. (1994) 
detected FOLR3 mRNA in certain carcinomas and in tissues that are sources for 
hematopoietic cells such as normal or malignant spleen, bone marrow, and thymus [36]. 
Progesterone receptor membrane component 1 (PGRMC1) is related to cytochrome b5, 
binds to heme, and is associated with DNA damage resistance and apoptotic suppression. 
PGRMC1 is induced by carcinogens, including dioxin, and is up-regulated in multiple 
types of cancer.  In a recent study, it was found that Pgrmc1 increased in vivo tumor 
growth, anchorage-independent growth, and migration [37].  Zou et al. (2007) reported 
that the hepatocyte growth factor receptor (HGFR) MET proto-oncogene plays an 
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important part in preventing FAS-mediated apoptosis of hepatocytes by sequestering FAS 
[38]; so, it may add some anti-apoptotic elements to keratinocytes in culture. 
In mouse models MET and VEGF have a synergistically positive effect on cell 
proliferation.  IL6 seems to increase expression of VEGF, and VEGF plus HGF has been 
shown to increase levels of IL-6, GRB10, PDGF, VEGFC and neuropilin (NRP1) [39].  
Overall a similar picture to what is observed in in vitro keratinocytes. 
Scavenger receptor BI (SR-BI) mediates the selective uptake of high density 
lipoprotein (HDL) cholesteryl ester (CE), a process by which HDL CE is taken into the 
cell without internalization and degradation of the HDL particle.  Low density 
lipoprotein-related protein 12 (LRP12) overexpression has been noted in oral squamous 
cell carcinomas[40].  This gene was identified by its differential expression in cancer 
cells.  The product of this gene is predicted to be a transmembrane protein.  The level of 
this protein was found to be lower in tumor derived cell lines compared to normal cells.  
This gene was thus proposed to be a candidate tumor suppressor gene.  
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Table 4a.  Receptors up-regulated in LCM [as compared to in vitro] 
Symbol Description FC 
log2 
FC P fdr 
in 
vitro LCM 
THRA thyroid hormone receptor, alpha  5.8 -2.55 0 0 3.69 6.23 
THRB thyroid hormone receptor, beta  4.8 -2.26 0 0 5.56 7.81 
PRLR prolactin receptor 5.4 -2.43 0 0 2.26 4.69 
INSR insulin receptor 5.2 -2.39 0 0 4.63 7.01 
FGFR3 fibroblast growth factor receptor  8.8 -3.14 0 0 10.85 13.99 
IL11RA interleukin 11 receptor, alpha 8.6 -3.11 0 0 4.15 7.26 
IL20RA interleukin 20 receptor, alpha 8.6 -3.11 0 0 3.54 6.65 
FGFR2 fibroblast growth factor receptor  4.1 -2.05 0 0 7.11 9.16 
IL1R1 interleukin 1 receptor, type I 15.3 -3.94 0 0 6.82 10.75 
IFNGR1 interferon gamma receptor 1 4.5 -2.17 0.001 0 3.57 5.73 
 
From the samples collected from frozen human skin by LCM we get a very 
different impression of the cytokine and growth factor milieu in vivo (Table 4b) than 
conclusions based on in vitro samples (Table 3a) would lead you to believe.  It is obvious 
that the keratinocytes are no longer within a living organism: their transcriptional circuits 
have been re-wired to survive in culture and the cells have lost much of the former gene 
expression that is critical to the proper functioning of the epidermis.  In vivo there are 
receptors for thyroid hormone (THRA, THRB,) that also function as transcription factors, 
prolactin (PRLR) which can play a role in apoptosis, and insulin (INSR,) a player in the 
MAPK pathway, that are all down-regulated in vitro by at least 5-fold compared to in 
vitro expression.  Several fibroblast growth factor receptors, FGFR2 and FGFR3, are 
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differentially expressed by about a log [of 10,] intimating their importance in vivo.  This 
data suggests a less important role for these receptors and their hormones when 
keratinocytes are cultured; the same seems to be true for cytokine receptors.  The receptor 
for IL-1 (IL1R1) is expressed 15 times higher in LCM samples as compared to the 
primary NHEK cell line.  The receptors for both IL-11 (IL11RA,) and IL-20 (IL20RA) 
are expressed at levels of almost 10-fold higher in vivo over the cultured cells.  In 
addition, the interferon gamma receptor (IFNGR1) expression level is 4 times higher in 
the dissected epidermis than in isolated keratinocytes that have only been passaged twice 
in vitro.  This shows how important in vivo study is for assessing paracrine, autocrine and 
immune system signals in the epidermis because any culture model, even primary cells 
that are not immortalized, creates many modifications due to the profound disparity in 
cellular environs. 
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Table 4b. 
Growth factors and chemokines up-regulated in LCM [as compared to in vitro] 
Symbol Description FC log2FC P fdr 
in 
vitro LCM 
CCL27 chemokine ligand 27 269 -8.074 0 0 3.81 11.88 
CXCL14 chemokine ligand 14 222 -7.794 0 0 2.54 10.33 
MAF 
musculoaponeurotic 
fibrosarcoma oncogene  214 -7.742 0 0 4.68 12.43 
BTC betacellulin 136 -7.085 0 0 2.38 9.47 
IL1F7 interleukin 1 family, member 7  35 -5.116 0 0 2.27 7.38 
CCRL1 chemokine receptorlike1 31 -4.967 0 0 2.42 7.38 
IL7 interleukin 7 29 -4.863 0 0 2.40 7.26 
BMP7 bone morphogenetic protein 7 24 -4.565 0 0 2.27 6.84 
KIT 
Hardy-Zuckerman feline 
sarcoma viral oncogene  13 -3.687 0 0 2.98 6.67 
IL33 interleukin 33 12 -3.538 0 0 2.56 6.10 
NOTCH3 Notch homolog 3  5 -2.377 0 0 5.82 8.19 
 
 
In terms of chemokines and other ligands for the cellular receptors there is a 
significant difference between what is produced in the skin versus in culture.  The 
primary receptor for BTC is the EGFR.  We see betacellulin (BTC) and MAF, which has 
positive regulatory functions on RNA polymerase II production, are both expressed more 
than 2 logs(base 10) higher in samples collected by LCM compared to the primary 
keratinocytes grown in vitro.  Expression of the multi-functional Notch homolog 3 gene 
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is also significantly elevated in vivo by 5-fold where it not only functions in Notch 
signaling, but also calcium binding, transcription and development.  IL-7, important in 
the humoral immune response and positively regulating proliferation of both B and T 
cells, is decreased by almost 30-fold in culture.  Similarly, IL-33, another important 
cytokine is down 12-fold in culture as compared to LCM samples.  CXCL14, which has 
signal transduction, intercellular communication and chemotaxis functionalities, is 
decreased by more than 200 times the LCM expression level in vitro.  CCL27, also 
important in chemotaxis, cell-cell signaling and in the immune response is detected at 
almost 300 times the amount found in culture.  The gene expression of CCRL1, 
interleukin 1 family, member 7(zeta) (IL1F7) which has IL-1R antagonistic abilities, is 
down-regulated in vitro by 35-fold.  Additionally, in cultured keratinocytes, growth 
factors such as bone morphogenetic protein 7 (BMP7) and KIT are each relatively 
expressed about 20 times lower than in normal human epidermis. 
 
 
Cell cycle and related genes of interest 
Genes expressed highly in LCM captured epidermis suggest a more regulated 
growth environment in vivo (Table 5b.)  Relative to the in vitro samples we see many 
more genes involved in cell cycle arrest as well as those that promote cell death 
(apoptosis) and negative regulators of transcription.  
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Table 5a.  Top cell cycle-related genes differentially expressed in culture 
 
Symbol Description FC log2FC P fdr 
in 
vitro LCM 
KRT18 keratin 18 608 9.25 0 0 12.38 3.13 
DKK1 dickkopf homolog 1  605 9.24 0 0 11.51 2.27 
G0S2 G0/G1switch 2 303 8.24 0 0 11.47 3.22 
TNFRSF21 TNF receptor superfamily, 21 229 7.84 0 0 11.61 3.77 
NRG1 neuregulin 1 160 7.32 0 0 9.96 2.64 
INHBA inhibin, beta A 131 7.04 0 0 9.46 2.43 
IGF2BP3 
insulin-like growth factor 2 
mRNA binding protein 3 130 7.02 0 0 9.55 2.53 
RAC2 ras-related C3 b.tox substrate 2  128 7.00 0 0 10.01 3.02 
LAMB3 laminin, beta 3 88 6.46 0 0 13.44 6.99 
FOSL1 FOS-like antigen 1 82 6.36 0 0 9.29 2.93 
CCND2 cyclin D2 72 6.16 0 0 10.83 4.67 
ODC1 ornithine decarboxylase 1 71 6.15 0 0 13.02 6.87 
RRAD Ras-related associated diabetes 70 6.13 0 0 8.76 2.63 
 
Looking specifically at genes related to cell cycle we see a distinct trend of less 
differentiated keratinocyte genes and architechture of the epithelium, upregulation of 
cyclins and genes that promote cell proliferation.  In addition to inhibition of apoptotic 
pathways including specifically Wnt antagonism, disregulation of many proto-oncogenes. 
members of the RAS superfamily and JUN family.  Many of these genes have already 
been reported in association with various cancers.  
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In regards to less differentiated genes we see KRT18, embryonic keratin most 
different N-terminal and C-terminal domains and location on chromosome 12q13 
suggests early divergence from other human type I keratins [41], clustered on 
chromosome 17.  Wnt signals are required for the initiation on hair follicle[42] and taste 
papilla development[43].  However in vitro we see high expression of DKK1, which is a 
Wnt antagonist[44] upregulated in serum of patients with multiple myeloma by playing a 
role in the inhibition of osteoclast differentiation[45].  Dkk1 has also been shown to 
progressively destroy the gastrointestinal epithelial architecture in mice[46].  NRG1 plays 
critical roles in the growth and development of multiple organ systems.  IGF2BP3 is the 
first biomarker of prognostic significance in ovarian clear cell carcinoma that has been 
validated in an independent case series[47].  
G0S2 acts as an inhibitor of ATGL activity and ATGL-mediated lipolysis[48].  
The G0S2 protein regulates apoptosis, while INHBA overexpression may promote cell 
proliferation[49].  Death domains like those of TNFRSF21 control cell apoptosis; and, 
highly expressed in many tumors and their cell lines[50].  The protein encoded by this 
RAC2 is a GTPase which belongs to the RAS superfamily of small GTP-binding 
proteins. Members of this superfamily appear to regulate a diverse array of cellular 
events, including the control of cell growth, cytoskeletal reorganization, and the 
activation of protein kinases.  The expression levels of LAMB3 mRNAs were higher in 
malignant tissues than in the corresponding normal tissues[51].  The Fos gene family 
consists of 4 members: FOS, FOSB, FOSL1, and FOSL2.  These genes encode leucine 
zipper proteins that can dimerize with proteins of the JUN family, thereby forming the 
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transcription factor complex AP-1.  As such, the FOS proteins have been implicated as 
regulators of cell proliferation, differentiation, and transformation [provided by RefSeq].   
Different cyclins exhibit distinct expression and degradation patterns which 
contribute to the temporal coordination of each mitotic event.  Cyclin D2 forms a 
complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is 
required for cell cycle G1/S transition.  CCND2 has been shown to interact with and be 
involved in the phosphorylation of tumor suppressor protein Rb.  Knockout studies of the 
homologous gene in mouse suggest the essential roles of this gene in ovarian granulosa 
and germ cell proliferation.  High level expression of this gene has been observed in 
ovarian and testicular tumors [provided by RefSeq].  ODC1 encodes the rate-limiting 
enzyme of the polyamine biosynthesis pathway which catalyzes ornithine to putrescine. 
The activity level for the enzyme varies in response to growth-promoting stimuli and 
exhibits a high turnover rate in comparison to other mammalian proteins [provided by 
RefSeq]. 
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Table 5b.  Top cell cycle-related genes differentially expressed in vivo 
P-value cut-off of 0.01   log2 of Fold Change>4            false discovery rate (fdr) 
Symbol Fold Elevation in LCM log2FC P fdr 
in 
vitro LCM 
CRIP1 662 9.37 0 0 3.11 12.48 
DAPL1 648 9.34 0 0 3.41 12.75 
ID4 481 8.91 0 0 2.32 11.23 
GAS7 89 6.48 0 0 4.67 11.15 
EGLN3 63 5.98 0 0 2.84 8.82 
HLF 56 5.80 0 0 2.26 8.06 
GAS1 53 5.72 0 0 4.71 10.43 
ST7L 36 5.16 0 0 2.72 7.88 
SGEF 30 4.93 0 0 5.21 10.14 
BCL2 26 4.70 0 0 3.17 7.87 
BNIPL 25 4.67 0 0 7.96 12.63 
FGD2 23 4.53 0 0 5.01 9.54 
C13orf15 22 4.47 0 0 3.46 7.93 
RRAGD 22 4.45 0 0 4.28 8.73 
RTN4 22 4.45 0 0 3.87 8.32 
PRKRA 21 4.42 0 0 3.52 7.94 
PER2 21 4.41 0 0 5.40 9.81 
GATA3 21 4.41 0 0 7.07 11.48 
WNT4 17 4.07 0 0 2.26 6.33 
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Cysteine-rich intestinal protein 1 (CRIP1) has been identified as a novel marker 
for early detection of cancers. CRIP is highly expressed in intestine and immune cells. 
Increased CRIP expression seen in response to LPS suggests that CRIP may play a role in 
immune cell activation or differentiation or in processes associated with cellular 
repair[52].   
The death-associated protein-like 1 or DAPL1 is an early epithelial 
differentiation-associated protein also involved in apoptosis.  ID4 is a negative regulator 
of transcription and therefore a potential tumour suppressor gene.  GAS1 overexpression 
is able to block cell proliferation in many cancer cell lines[53].  The effect is mediated by 
p53[54] and GAS1 is a positive regulator of the Sonic hedgehog signaling pathway[55] 
and has been proposed as a potential melanoma metastasis suppressor[56].  The Gas 7 
protein increases markedly during growth arrest of NIH3T3 cells and persists transiently 
at high levels upon re-entry of cells into the cell cycle.  Growth arrest-specific (gas) genes 
are expressed preferentially in cells that enter a quiescent state.  gas7, which was 
identified in serum-starved murine fibroblasts, was reported to be expressed in vivo 
selectively in neuronal cells of the mature cerebral cortex, hippocampus, and cerebellum. 
gas7 transcripts encode a 48-kDa protein containing a structural domain that resembles 
sequences of OCT2, a POU transcription factor implicated in neuronal development and 
synapsins, which have a role in modulating neurotransmitter release[57].  EGLN2, Rat 
Sm-20 is a homologue of the Caenorhabditis elegans gene egl-9 and has been implicated 
in the regulation of growth, differentiation and apoptosis in muscle and nerve cells.  HLF 
is a well known proto-oncogene.  Wild-type Hlf is able to bind DNA specifically as a 
homodimer or as a heterodimer with other PAR factors.  Structural alterations of the E2a-
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Hlf fusion protein markedly impair its ability to bind DNA as a homodimer compared 
with wild-type Hlf[58].  ST7L gene was identified by its similarity to the ST7 tumor 
suppressor gene, which is clustered with WNT2 gene in the chromosome 7q31 region. 
Because allelic loss or rearrangements of human chromosome 1p13 region are reported in 
breast cancer, germ cell tumors, squamous cell carcinoma of head and neck, non-small 
cell lung cancer, gastrointestinal stromal/smooth muscle tumors (GIST), meningioma, 
melanoma, acute megakaryoblastic leukemia (M7), and Kaposi's sarcoma, ST7R might 
be a novel tumor suppressor gene on human chromosome 1p13[59].  Src homology 3 
domain-containing guanine nucleotide exchange factor (SGEF).  A particularly 
interesting characteristic of the SGEF gene is that it produces two transcripts, one of 
which encodes a protein with the structural features typical of other Rho GEFs.  The 
second transcript encodes a much shorter protein that could function as a modulator of 
Rho GEF activity[60].  BCL2 deregulation prolongs cell survival as it normally regulates 
apoptosis in cells and is considered to be a proto-oncogene; though, it does not play a role 
in proliferation[61].  BNIPL or BCL2/Adenovirus E1B 19-KD Protein-Interacting 
Protein 2-Like also suppresses cell growth by inducing apoptosis[62].  FGD2 is 
expressed in antigen-presenting cells, including B lymphocytes, macrophages, and 
dendritic cells.  Response Gene To Complement 32 (RGC32) or C13ORF15 is a cell 
cycle regulatory factor that mediates cell proliferation, both as an activator and substrate 
of CDC2[63].  RRAGD is a monomeric guanine nucleotide-binding protein, or G protein.  
By binding GTP or GDP, small G proteins act as molecular switches in numerous cell 
processes and signaling pathways.  The product of the RTN4 gene is a potent neurite 
outgrowth inhibitor that may also help block the regeneration of the central nervous 
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system in higher vertebrates.  Alternatively spliced transcript variants derived both from 
differential splicing and differential promoter usage and encoding different isoforms have 
been identified [RefSeq].  Reticulons are, so far, the only molecules to participate in all 
three apoptosis signaling pathways.  PRKRA encodes a protein kinase activated by 
double-stranded RNA, which mediates the effects of interferon, particulatly in response 
to viral infection.  Cellular protein may be a stress-activated, physiologic activator of 
PKR that couples transmembrane stress signals and protein synthesis[64].  The 
expression of Per1 and Per2 in glioma cells was much lower than in the surrounding non-
glioma cells.  Therefore, disturbances in Per1 and Per2 expression may result in the 
disruption of the control of normal circadian rhythm, thus benefiting the survival of 
glioma cells.  The growth of stable PER2 transformants in vivo was significantly and 
dose-dependently suppressed according to the amount of PER2 expressed, indicating that 
PER2 plays a role in the growth suppression of sarcoma cells[65].  The GATA3 protein 
contains two GATA-type zinc fingers and is an important regulator of T-cell 
development and plays an important role in endothelial cell biology.  GATA3 drives 
invasive breast cancer cells to undergo the reversal of epithelial-mesenchymal transition, 
leading to the suppression of cancer metastasis[66].  WNT4 is a member of the wingless-
type MMTV integration site family that encodes secreted signaling proteins that have 
been implication in regulation of cell fate.  Proliferation-related to Ki-67 antigen 
(MKi67) expression was also most highly expressed in in vitro keratinocyte cultures, 
probably due to the constitutive activation by growth media sold from PromoCell. 
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Conclusions 
 Taken together we can see that the epidermis, precisely isolated from the dermis 
by LCM, provides a much more accurate genomic picture of human keratinocytes than 
primary cell lines.  The caveat of this methodology, however, is that you also isolate 
melanocytes and Langerhans cells present at low levels in the epidermis. 
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Chapter 3.  FACS to isolate skin cells before culture 
 
Theory and aims 
The gene expression of a normal, “resting” keratinocyte is difficult to define due 
to the limitations of the available methods.  Cultured keratinocytes are exposed to 
conditions so dissimilar from their normal environment that their gene expression does 
not represent their in vivo counterparts.  Laser capture microscopy (LCM) mitigates this 
problem because the keratinocytes are processed immediately after they are isolated from 
frozen tissue.  Unfortunately, LCM is limited by the contamination by other cells in the 
epidermis such as melanocytes, Langerhans cells, and Merkel cells.  In order overcome 
the above limitations, we employed fluorescence activated cell sorting (FACS) to isolate 
keratinocytes from human skin for gene analysis and comparison.  This method virtually 
eliminates the possibility that other cells from the epidermis will contaminate the gene 
expression signatures of the samples.  The keratinocytes are cultured for only a short 
period of time before analysis, and therefore, there are fewer variations in gene 
expression compared to traditionally cultured cells.   
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Results 
 Table 6b shows gene expression levels in FACS-derived keratinocytes 
relative to LCM epidermis and to cultured keratinocytes.  The table is organized to show 
genes up-regulated in FACS-derived keratinocytes relative to LCM epidermis or to show 
genes up-regulated in LCM epidermis relative to FACS-derived keratinocytes (Table 6a).         
Briefly, it is expected that genes specific to the outermost non-viable cell layers of 
the epidermis would not be detected in FACS samples, and only basal and lower spinous 
level of keratinocytes would be collected after tissue dissociation.  Therefore, proteins 
characteristic of the upper spinous, granular and corneocytic layers (e.g. late cornified 
envelope proteins, loricrin, filaggrin, desmoglein, sciellin, enveloplakin and decorin) are 
highly upregulated in LCM epidermis as compared to FACS keratinocytes.  Similarly, 
tight junctions and any other intercellular connections would be disrupted by the creation 
of a single cell suspension, as is necessary for proper FACS experimental function.  Tight 
junctions regulate movement of solutes and ions through the paracellular space and 
prevent mixing of proteins and lipids in the outer leaflet of the apical and basolateral 
plasma membrane domains.  Claudins, such as CLDN8 (whose RNA is almost 20 times 
higher in epidermis than in FACS cell suspension), are components of epithelial cell tight 
junctions.  
EGFR ligands are autocrine-acting growth factors for keratinocytes, playing a 
central role in controlling proliferation of these cells [67,68] [69] [70,71,72].  Member of 
the EGF family [which is known to play an important role in skin morphogenesis, 
homeostasis and repair] growth factor betacellulin (BTC) is highly expressed in LCM as 
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compared to FACS, while its primary receptor EGFR is not differentially expressed with 
any significance.  There is abundant evidence that normal development and homeostasis 
of the skin and its appendages, specifically of hair follicles, depend on the correct 
expression and activity of the EGFR and its ligands; so, our data that EGFR is not 
significantly up or down-regulated seems to fit in normal skin LCM samples.    Over-
expression of the EGFR has been detected in epithelial squamous cell carcinomas [73,74] 
and in psoriasis [75,76], and substantial evidence implicates ErbB signaling as a major 
component in the pathogenesis of non-melanoma skin cancer[77] [78]; and, 
overexpression of multiple EGFR ligands occurs in psoriatic epidermis [70,79,80,81] but 
these LCM samples are from non-lesional skin. LRP4, a protein that contains multiple 
EGF-like domains[82], which are believed to play a critical role in a number of 
extracellular events, including cell adhesion and receptor-ligand interactions, is also 
detected in vivo.    
Many molecules that interact with the organism as a whole (eg immunity) are 
detected in situ.  Chemoattractant signal transducer ITPR2 is expressed more than 25 
times higher in LCM epidermis than in FACS keratinocytes.  Selective monocyte 
chemoattractant CXCL14 [83] is high in LCM epidermis: expression is 60 times lower in 
FACS keratinocytes.  RORC, a member of the nuclear receptor gene superfamily that 
encodes transcriptional regulators that play critical roles during homeostasis, is detected 
in LCM epidermis.  In particular the decision of antigen-stimulated cells to differentiate 
into either TH-17 or T(reg) cells depends on the cytokine-regulated balance of RORC 
and Foxp3[84].  S1P (a lipid mediator and regulator of cell proliferation) degrading 
enzyme SGPP2 is present almost 50 times higher in LCM samples.    
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Table 6a.  Genes up-regulated in LCM epidermis v. FACS keratinocytes  
P-value cut-off of 0.01   log2FC of Fold Change>4          false discovery rate (fdr) 
Symbol Description FC lgF
C 
LC
M
/FA
CS
 
P 
f
d
r FACS LCM 
FLG2 filaggrin family member 2 4860 12.25 0 0 3.14 15.38 
LOR loricrin 783 9.61 0 0 4.60 14.22 
FLG filaggrin 446 8.80 0 0 5.53 14.34 
LCE2B late cornified envelope 2B 137 7.10 0 0 3.59 10.69 
HLA-
DQB2 
major histocompatibility 
complex, class II, DQ beta 2 108 6.76 0 0 2.66 9.41 
BTC betacellulin 100 6.65 0 0 2.82 9.47 
BCL11A B-cell CLL/lymphoma 11A  83 6.38 0 0 3.09 9.47 
CXCL14 chemokine ligand 14 61 5.92 0 0 4.41 10.33 
CD1A CD1a molecule 57 5.84 0 0 2.27 8.11 
FCER1A 
Fc fragment of IgE, high 
affinity I, receptor for; alpha  53 5.74 0 0 2.28 8.01 
LCE1B late cornified envelope 1B 49 5.62 0 0 8.35 13.97 
HLA-
DPB1 
major histocompatibility 
complex, class II, DP beta 1 49 5.62 0 0 4.08 9.69 
CD207 CD207 molecule, langerin 49 5.62 0 0 2.31 7.92 
SGPP2 
sphingosine-1-phosphate 
phosphotase 2 48 5.58 0 0 3.16 8.74 
COL21A1 collagen, type XXI, alpha 1 42 5.40 0 0 3.42 8.82 
KRT73 keratin 73 38 5.24 0 0 2.26 7.50 
CRIP1 
cysteine-rich protein 1 
(intestinal) 35 5.12 0 0 7.37 12.48 
CIRBP cold inducible RNA b.p. 34 5.09 0 0 2.94 8.03 
 
 
51 
Symbol Description FC log2FC  P 
f
d
r FACS LCM 
IL1F7 interleukin 1 family, 7 (zeta) 30 4.92 0 0 2.27 7.20 
KLF8 Kruppel-like factor 8 29 4.84 0 0 6.33 11.16 
KRT77 keratin 77 28 4.82 0 0 7.58 12.40 
RORC RAR-related orphan receptor  27 4.77 0 0 3.20 7.97 
LRP4 
low density lipoprotein 
receptor-related protein 4 27 4.76 0 0 7.42 12.19 
HLA-DRA 
major histocompatibility 
complex, class II, DR alpha 27 4.74 0 0 2.70 7.44 
TNFRSF19 
tumor necrosis factor receptor 
sf, member 19 26 4.71 0 0 7.76 12.48 
ITPR2 inositol 1,4,5-triP receptor, 2 26 4.71 0 0 6.52 11.24 
RASA4 RAS p21 protein activator 4 23 4.52 0 0 3.20 7.72 
CD74 HLA-DR-gamma 21 4.39 0 0 5.55 9.94 
HYMAI hydatidiform mole associated  21 4.38 0 0 3.19 7.57 
HLA-
DPA1 
major histocompatibility 
complex, class II, DP alpha 1 21 4.37 0 0 3.92 8.29 
LTB4R leukotriene B4 receptor 20 4.34 0 0 5.10 9.44 
CPVL 
carboxypeptidase,   
vitellogenic-like 20 4.31 0 0 2.74 7.05 
BCHE butyrylcholinesterase 19 4.25 0 0 4.58 8.83 
CLDN8 claudin 8 18 4.21 0 0 4.46 8.67 
SGEF 
Src homology 3 guanine 
nucleotide exchange factor 18 4.20 0 0 5.93 10.14 
POSTN periostin, osteoblast factor 18 4.14 0 0 3.13 7.27 
HLF hepatic leukemia factor 18 4.13 0 0 4.71 8.84 
OSTF1 osteoclast stimulating factor1 17 4.12 0 0 4.82 8.94 
SCAI suppressor cancer invasion 17 4.11 0 0 3.88 7.98 
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Symbol Description FC log2FC  P 
f
d
r FACS LCM 
IGFBP5 insulin-like gf bp 5 16 3.98 0 0 4.83 8.81 
LY75 lymphocyte antigen 75 16 3.98 0 0 4.45 8.43 
ORMDL1 ORM1-like 1 (S. cerevisiae) 16 3.97 0 0 3.23 7.20 
HLA-
DQB1 
major histocompatibility 
complex, class II, DQ beta 1 16 3.96 0 0 2.77 6.73 
MAF 
v-maf musculoaponeurotic 
fibrosarcoma oncogene  15 3.95 0 0 4.58 8.53 
PLAGL1 ZAC tumor suppressor 15 3.93 0 0 6.12 10.06 
RHOBTB3 
Rho-related BTB             
domain containing 3 15 3.91 0 0 4.07 7.98 
FGFR3 fibroblast gf receptor 3 15 3.87 0 0 10.13 13.99 
HLA-
DQA1 
major histocompatibility 
complex, class II, DQ alpha1 14 3.79 0 0 2.26 6.06 
EML5 
echinoderm microtubule 
associated protein like 5 14 3.79 0 0 2.44 6.23 
TGFBR3 
transforming growth factor, 
beta receptor III 14 3.76 0 0 6.38 10.14 
TNNT2 troponin T type 2 (cardiac) 13 3.73 0 0 3.69 7.42 
TPD52 tumor protein D52 13 3.69 0 0 4.03 7.72 
PSORS1C2 
psoriasis susceptibility 1 
candidate 2 13 3.67 0 0 2.39 6.06 
DNAJC24 
DnaJ (Hsp40) homolog, 
subfamily C, member 24 13 3.66 0 0 2.46 6.12 
MUC15 mucin 15, cell surface ass. 12 3.64 0 0 4.29 7.93 
TPRG1 tumor protein p63 regulated1 12 3.63 0 0 6.79 10.42 
MAGEE1 melanoma antigen family E,1 12 3.62 0 0 3.16 6.78 
PBX1 pre-B-cell leukemia homeobox  12 3.59 0 0 3.03 6.62 
AGR3 anterior gradient homolog 3  12 3.58 0 0 2.26 5.84 
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Symbol Description FC log2FC  P 
f
d
r FACS LCM 
POF1B premature ovarian failure, 1B 12 3.57 0 0 3.37 6.94 
IL20RA interleukin 20 receptor, alpha 12 3.55 0 0 3.10 6.65 
IL7 interleukin 7 12 3.55 0 0 3.72 7.26 
PIK3C2G 
phosphoinositide-3-kinase, 
class 2, gamma polypeptide 12 3.54 0 0 4.08 7.61 
RICS Rho GTPase-activating  12 3.53 0 0 6.38 9.92 
RORA RAR-related orphan receptor  11 3.52 0 0 8.78 12.30 
MAP2K5 
mitogen-activated protein 
kinase kinase 5 11 3.49 0 0 2.40 5.89 
DSG1 desmoglein 1 11 3.48 0 0 10.24 13.72 
RAB7B 
RAB7B, member RAS 
oncogene family 11 3.48 0 0 5.43 8.91 
MYCBP2 MYC binding protein 2 11 3.48 0 0 9.24 12.72 
PCDH21 protocadherin 21 11 3.47 0 0 2.90 6.37 
DCN decorin 11 3.47 0 0 4.98 8.45 
TCEA3 
transcription elongation factor 
A (SII), 3 11 3.46 0 0 7.72 11.19 
ST7L 
suppression of tumorigenicity  
7 like 11 3.45 0 0 4.44 7.88 
KCND3 
potassium voltage-gated 
channel, member 3 11 3.45 0 0 4.21 7.66 
MAP3K2 
mitogen-activated protein 
kinase kinase kinase 2 11 3.44 0 0 7.18 10.62 
SCEL sciellin 11 3.42 0 0 8.65 12.07 
CDSN corneodesmosin 11 3.40 0 0 7.50 10.90 
GATA3 GATA binding protein 3 10 3.38 0 0 8.09 11.48 
CAT catalase 10 3.38 0 0 8.88 12.26 
KRT2 keratin 2 10 3.36 0 0 11.17 14.53 
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Symbol Description FC log2FC  P 
f
d
r FACS LCM 
ALDH3A2 
aldehyde dehydrogenase 3 
family, member A2 10 3.34 0 0 4.73 8.07 
COL3A1 collagen, type III, alpha 1 10 3.34 0 0 2.53 5.87 
DAPL1 death ass protein-like 1 10 3.34 0 0 9.41 12.75 
GPRIN2 
G protein regulated inducer of 
neurite outgrowth 2 10 3.31 0 0 2.48 5.79 
HLA-
DRB4 
major histocompatibility 
complex, class II, DR beta 4 10 3.30 0 0 6.59 9.89 
COBL cordon-bleu homolog  10 3.29 0 0 7.12 10.42 
PTGER3 prostaglandin E receptor 3  10 3.29 0 0 5.87 9.16 
NOL3 
nucleolar protein 3      
(apoptosis repressor) 10 3.29 0 0 5.01 8.29 
CHD1L 
chromodomain helicase DNA 
binding protein 1-like 10 3.28 0 0 3.89 7.17 
IDE insulin-degrading enzyme 10 3.28 0 0 6.17 9.45 
SYTL2 synaptotagmin-like 2 10 3.26 0 0 5.43 8.69 
ALOX12 arachidonate 12-lipoxygenase 9 3.23 0 0 3.87 7.10 
HCRP1 
hepatocellular carcinoma-
related HCRP1 9 3.22 0 0 2.44 5.66 
TIA1 
TIA1 cytotoxic granule-
associated RNA bp 9 3.21 0 0 6.60 9.81 
STAR 
steroidogenic acute     
regulatory protein 9 3.18 0 0 2.68 5.86 
PIK3C2B 
phosphoinositide-3-kinase, 
class 2, beta polypeptide 9 3.15 0 0 7.90 11.05 
BCL11B B-cell CLL/lymphoma 11B  9 3.15 0 0 7.74 10.89 
PGRMC2 
progesterone receptor 
membrane component 2 9 3.14 0 0 8.75 11.89 
ATL2 atlastin GTPase 2 9 3.10 0 0 6.46 9.56 
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Symbol Description FC log2FC  P 
f
d
r FACS LCM 
HSPC159 galectin-related protein 8 3.08 0 0 10.84 13.92 
RCOR3 REST corepressor 3 8 3.08 0 0 6.89 9.98 
BCLAF1 BCL2-associated t.f.1 8 3.06 0 0 2.76 5.82 
KIN 
KIN, antigenic determinant of 
recA protein homolog  8 3.05 0 0 2.63 5.68 
MCF2L 
MCF.2 cell line derived 
transforming sequence-like 8 3.05 0 0 4.39 7.43 
ANKH ankylosis (mouse) 8 3.03 0 0 4.76 7.79 
CLNS1A 
chloride channel, nucleotide-
sensitive, 1A 8 3.02 0 0 4.88 7.90 
AHSA2 
activator of heat shock 90kDa 
protein ATPase 2  8 3.02 0 0 3.04 6.06 
NSMAF 
neutral sphingomyelinase 
activation associated factor 8 3.01 0 0 3.61 6.62 
POU2F3 POU class 2 homeobox 3 8 2.99 0 0 4.13 7.12 
SYT17 synaptotagmin XVII 8 2.99 0 0 2.29 5.27 
ACER1 alkaline ceramidase 1 8 2.96 0 0 2.51 5.47 
ACBD5 
acyl-Coenzyme A binding 
domain containing 5 8 2.96 0 0 5.13 8.09 
BCOR BCL6 co-repressor 8 2.94 0 0 5.25 8.19 
RHOT1 ras homolog gene family, T1 7 2.91 0 0 8.39 11.29 
PTGS1 
prostaglandin-endoperoxide 
synthase 1  7 2.88 0 0 7.85 10.73 
BMS1P5 BMS1 pseudogene 5 7 2.87 0 0 3.10 5.97 
EVL Enah/Vasp-like 7 2.87 0 0 3.59 6.45 
ELL3 
elongation factor RNA 
polymerase II-like 3 7 2.84 0 0 9.18 12.01 
NFASC neurofascin homolog  7 2.83 0 0 2.64 5.46 
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Symbol Description FC log2FC  P 
f
d
r FACS LCM 
TAF15 
TAF15 RNA polymerase II, 
TATA (BP)-associated factor 7 2.83 0 0 5.49 8.32 
GRTP1 
growth hormone regulated  
TBC protein 1 7 2.81 0 0 7.84 10.65 
KIFC2 kinesin family member C2 7 2.81 0 0 7.24 10.04 
TNFSF10 TNF (ligand) 10 7 2.80 0 0 6.99 9.79 
MEF2A myocyte enhancer factor 2A 7 2.80 0 0 6.39 9.18 
RAB12 RAS oncogene family 7 2.79 0 0 4.36 7.15 
NMNAT3 
nicotinamide nucleotide 
adenylyltransferase 3 7 2.78 0 0 4.81 7.60 
EVPL envoplakin 7 2.78 0 0 7.42 10.20 
TP53AIP1 
tumor protein p53 regulated 
apoptosis inducing protein 1 7 2.76 0 0 2.65 5.42 
NPY1R neuropeptide Y receptor Y1 7 2.76 0 0 4.97 7.73 
FGL2 fibrinogen-like 2 7 2.73 0 0 2.88 5.61 
PDCD5 programmed cell death 5 7 2.72 0 0 4.54 7.26 
BMP7 bone morphogenetic protein7 7 2.72 0 0 4.12 6.84 
MNDA 
myeloid cell nuclear 
differentiation antigen 7 2.71 0 0 2.63 5.35 
GAS1 growth arrest-specific 1 7 2.70 0 0 7.72 10.43 
AGBL3 ATP/GTP bp-like 3 7 2.70 0 0 2.37 5.08 
TET2 tet oncogene family 2 6 2.67 0 0 4.36 7.02 
KRAS 
v-Ki-ras2 Kirsten rat      
sarcoma viral oncogene  6 2.67 0 0 3.85 6.52 
CCRL1 chemokine receptor-like 1 6 2.67 0 0 4.72 7.38 
CCL27 chemokine ligand 27 6 2.65 0 0 9.23 11.88 
RAB2A RAS oncogene family 6 2.65 0 0 2.86 5.51 
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Symbol Description FC log2FC  P 
f
d
r FACS LCM 
EPPK1 epiplakin 1 6 2.65 0 0 6.64 9.29 
MSTP9 
macrophage stimulating, 
pseudogene 9 6 2.64 0 0 5.47 8.10 
KIAA1704 KIAA1704 6 2.59 0 0 3.79 6.38 
KRT72 keratin 72 6 2.58 0 0 2.28 4.87 
POLR2J4 polymerase (RNA) II J4 6 2.56 0 0 5.43 7.99 
KIAA0494 KIAA0494 6 2.55 0 0 3.90 6.46 
E2F2 E2F transcription factor 2 6 2.54 0 0 4.09 6.63 
MAP3K1 MAPK kinase kinase 1 6 2.53 0 0 3.56 6.10 
MAP3K6 
mitogen-activated protein 
kinase kinase kinase 6 6 2.53 0 0 7.37 9.91 
RAB27B RAS oncogene family 6 2.53 0 0 10.16 12.69 
RASAL1 RAS protein activator like 1  6 2.53 0 0 2.48 5.01 
SP8 Sp8 transcription factor 6 2.53 0 0 3.29 5.82 
DNAJB2 DnaJ (Hsp40) homolog, B, 2 6 2.48 0 0 8.02 10.51 
MCTS1 
malignant T cell           
amplified sequence 1 6 2.48 0 0 3.47 5.95 
BNIPL 
BCL2/adenovirus E1B 19kD 
interacting protein like 5 2.46 0 0 10.18 12.63 
HRASLS HRAS-like suppressor 5 2.44 0 0 3.86 6.30 
CFD complement factor D (adipsin) 5 2.43 0 0 5.43 7.86 
FARP2 
FERM, RhoGEF and pleckstrin 
domain protein 2 5 2.42 0 0 5.40 7.82 
CHD9 
chromodomain helicase DNA 
binding protein 9 5 2.41 0 0 8.46 10.87 
CNGA1 
cyclic nucleotide gated   
channel alpha 1 5 2.39 0 0 2.98 5.37 
KLK1 kallikrein 1 5 2.39 0 0 5.19 7.58 
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Symbol Description FC log2FC  P 
f
d
r FACS LCM 
KIAA1712 KIAA1712 5 2.38 0 0 7.67 10.05 
GAS7 growth arrest-specific 7 5 2.37 0 0 8.78 11.15 
DIO2 
deiodinase, iodothyronine,   
type II 5 2.37 0.001 0 4.95 7.31 
CD36  (thrombospondin receptor) 5 2.33 0.001 0 2.78 5.11 
TNRC6A 
trinucleotide repeat    
containing 6A 5 2.33 0 0 3.10 5.43 
CD47 CD47 molecule 5 2.33 0 0 5.51 7.83 
CLCA4 chloride channel accessory 4 5 2.33 0 0 5.73 8.06 
KCNJ2 
potassium inwardly-rectifying 
channel J 2 5 2.32 0 0 5.41 7.73 
EFNA4 ephrin-A4 5 2.32 0 0 5.72 8.04 
FABP7 fatty acid binding protein 7 5 2.31 0 0 2.83 5.13 
LST1 leukocyte specific transcript 1 5 2.30 0 0 2.58 4.87 
PDCD4 
programmed cell death 4 
(neoplastic transformation 
inhibitor) 5 2.28 0 0 8.01 10.29 
MYCL1 
v-myc myelocytomatosis 1, 
lung carcinoma derived  5 2.28 0 0 5.76 8.04 
DCAF4 DDB1/CUL4 ass factor 4 5 2.27 0 0 3.06 5.33 
NAIP apoptosis inhibitory protein 5 2.27 0 0 4.18 6.45 
BAG1 BCL2-associated athanogene 5 2.26 0 0 7.76 10.02 
MST1 
macrophage stimulating 1 
(HGF-like) 5 2.25 0 0 6.32 8.57 
THRA 
thyroid hormone receptor, a 
(erythroblastic leukemia) 5 2.24 0 0 4.00 6.23 
VIPR1 
vasoactive intestinal        
peptide receptor 1 5 2.21 0 0 3.94 6.15 
KIAA1543 KIAA1543 5 2.20 0 0 4.19 6.39 
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f
d
r FACS LCM 
PRLR prolactin receptor 5 2.20 0 0 2.49 4.69 
CHI3L1 chitinase 3-like 1  5 2.18 0 0 7.98 10.15 
CIDEB cell death-inducing effector b 4 2.17 0 0 4.93 7.10 
IL11RA interleukin 11 receptor, alpha 4 2.16 0 0 5.10 7.26 
MLL3 
myeloid/lymphoid or       
mixed-lineage leukemia 3 4 2.15 0 0 6.68 8.83 
VPRBP Vpr (HIV-1) binding protein 4 2.15 0 0 4.83 6.98 
POU6F1 POU class 6 homeobox 1 4 2.15 0 0 3.20 5.34 
CIR1 corepressor with RBPJ, 1 4 2.14 0 0 4.92 7.06 
RABGAP1 
RAB GTPase activating   
protein 1-like 4 2.13 0 0 4.14 6.27 
CEP68 centrosomal protein 68kDa 4 2.12 0 0 6.72 8.84 
ARRB1 arrestin, beta 1 4 2.11 0 0 4.39 6.51 
PAQR5 
progestin and adipoQ receptor 
family member V 4 2.10 0 0 4.23 6.33 
STAG1 stromal antigen 1 4 2.09 0 0 2.88 4.97 
HLA-DMB 
major histocompatibility 
complex, class II, DM beta 4 2.09 0 0 3.36 5.45 
EPHA4 EPH receptor A4 4 2.07 0 0 6.11 8.18 
NOTCH3 Notch homolog 3  4 2.07 0 0 6.13 8.19 
RPRML reprimo-like 4 2.06 0 0 2.31 4.37 
CUL4A cullin 4A 4 2.02 0 0 4.43 6.46 
BOC Boc homolog (mouse) 4 2.01 0 0 4.35 6.35 
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There are caveats to the technique of LCM.  Though we attempt to avoid 
collecting hair follicles and other skin appendages in LCM there is some contamination; 
for example, keratin 73 (type II keratins that are specifically expressed in the inner root 
sheath of hair follicles) is still detected at relatively high levels.  Similarly, Keratin 77 (or 
K1b,) strongly expressed in the ducts of eccrine sweat glands [85,] was also detected in 
LCM where the deeper parts of the gland would have been captured unintentionally.  
CIRBP is a cold-shock protein in human cells[86] that wa elevated, which could be 
induced during the freezing process of skin samples in preparation for LCM.  It was also 
not surprising to see melanocyte products as well as many different major 
histocompatibility genes, CD207, LY75 and CD1a detected in LCM epidermis as the 
samples are not a pure keratinocyte cells due to inherent technological error.  The 
resolution of the microscope with H&E staining may not be of high enough quality to 
precisely segregate the basal layer of keratinocytes; this may also be due to the limitation 
of precision in the laser and the exactitude with which it dissects.  This shows the 
limitation of the method, although, the keratinocyte gene expression can still be readily 
distinguished from that of Langerhans cells due to their vastly variant biology. 
Surprisingly, many inflammation-related and growth growth genes became highly 
up-regulated after keratinocytes were dissociated and subjected to short-term incubation 
of suspension cultures.  Table 6b. is organized by high expression in FACS keratinocyte 
samples, but fold change (FC) is also listed.  CCL20, arguably the most important 
molecule in cutaneous inflammation, was up-regulated 3 logs in FACS over LCM.  
Expression levels of S100A9, an extremely imflammatory protein of innate immunity, 
and its heterodimeric protein complex partner, S100A8 were both increased over 100-
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fold in FACS samples as contrasted to LCM.  The production of many of these 
immunologic transcripts detected have been ascribed to other types of resident skin cells; 
so, this unique view point shows the true potential of the keratinocyte.  IL1RL1, 
associated with atopic dermatitis, was detected here 3-logs higher in FACS samples than 
LCM.  Expressed at similarly high levels relative to ‘in vivo’ LCM was neutrophil 
chemotaxic cytokine IL-8.  Heat shock proteins 70 (Hsp70) and 90 (Hsp90) recently 
identified in tape-stripping experiments were observed[87] here as well.   The FACS 
technique could be argued as a non-physiological equivalent to the wound healing 
response and reveals previously un-established aspects of keratinocyte plasticity.  
Keratin 6B, which dimerizes with keratin 17, is associated with hyperproliferative 
states and its expression was increased almost 3 logs in FACS keratinocytes as compared 
to LCM epidermis.  Among the members of the cytokeratin subfamily of intermediate 
filament (IF) proteins, keratin 17 is remarkable since it is normally expressed in the basal 
cells of complex epithelia, but not in stratified or simple epithelia; therefore indicative of 
a certain type of epithelial 'stem cell.'  Here it is remarkable because it was rapidly 
induced in wounded stratified epithelia.  SPRR1A is a member of the EDC induced in 
differentiating keratinocytes, here it was notable for its 20-fold increased expression level 
in FACS over LCM ‘in situ’ conditions, potentially suggesting an attempt at regeneration 
within the dissociated keratinocyte suspension. 
There are many growth and transcription factors up-regulated as well which 
support the idea of early activation response in FACS samples.  AREG and HBEGF 
expression is augmented approximately 400-fold in FACS as contrasted to LCM 
epidermis.  CXCL1 and CXCL2 are postulated melanocyte growth factors, showing the 
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attempt of the individual keratinocyte to regenerate the epidermis. ATF3 and JUN 
especially are known for their potent transcriptional activation.  Adrenomedullin has been 
reported to be induced under hypoxic conditions[88] and has roles in vasodilation, 
angiogenesis as well as growth modulation. 
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Table 6b.   Genes up-regulated in FACS keratinocytes v. LCM epidermis 
P-value cut-off of 0.01   Log2 of Fold Change>4            false discovery rate (fdr) 
 
Symbol Description FC log2FC  P 
f
d
r FACS LCM 
S100A8 S100 calcium binding protein A8 129 7.01 0 0 14.20 7.19 
HSPA6 heat shock protein 6 HSP70B 89 6.47 0 0 14.03 7.56 
KRT17 keratin 17 73 6.19 0 0 14.03 7.84 
IL1RL1 interleukin 1 receptor-like 1 2659 11.38 0 0 13.98 2.60 
ATF3 activating transcription factor 3 93 6.55 0 0 13.92 7.37 
ADM adrenomedullin 25 4.65 0 0 13.82 9.17 
SPRR1A small proline-rich protein 1A 21 4.36 0 0 13.77 9.41 
CCL20 chemokine ligand 20 1909 10.90 0 0 13.76 2.86 
KRT6B keratin 6B 883 9.79 0 0 13.70 3.91 
IGFBP3 insulin-like growth factor bp 3 6 2.56 0 0 13.59 11.03 
JUN jun oncogene 125 6.96 0 0 13.43 6.46 
IL8 interleukin 8 2005 10.97 0 0 13.35 2.38 
AREG amphiregulin 431 8.75 0 0 13.23 4.48 
GADD45A 
growth arrest and DNA-damage-
inducible, alpha 25 4.64 0 0 13.21 8.57 
GADD45B 
growth arrest DNA-damage-
inducible, beta 72 6.18 0 0 13.20 7.02 
TNFAIP3 
tumor necrosis factor, alpha-
induced protein 3 97 6.61 0 0 12.96 6.35 
HSPA6 heat shock protein 6 (HSP70B) 368 8.52 0 0 12.89 4.36 
S100A7 S100 calcium binding protein A7 57 5.84 0 0 12.86 7.02 
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Symbol Description FC log2FC  P 
f
d
r FACS LCM 
S100A9 S100 calcium binding protein A9 187 7.55 0 0 12.65 5.10 
DDIT4 DNAdamage-inducible transcript  31 4.96 0 0 12.51 7.55 
KRT16 keratin 16 39 5.30 0 0 12.46 7.16 
IL1F9 interleukin 1 family, member 9 36 5.15 0 0 12.42 7.27 
IRF6 interferon regulatory factor 6 27 4.76 0 0 12.33 7.57 
FOS FBJ osteosarcoma viral oncogene  11 3.43 0 0 12.22 8.79 
MAP3K8 
mitogen-activated protein kinase 
kinase kinase 8 6 2.67 0 0 12.20 9.53 
NFIL3 nuclear factor, IL3 regulated 51 5.67 0 0 12.13 6.46 
ISG20 IFN stimulated gene  134 7.07 0 0 12.09 5.02 
HBEGF heparin-binding EGF-like GF 342 8.42 0 0 12.08 3.67 
HSPA8 heat shock 70kDa protein 8 26 4.71 0 0 11.98 7.27 
FOSB FBJ osteosarcoma oncogene B 67 6.06 0 0 11.77 5.70 
IFRD1 IFN-related dev regulator 1 30 4.89 0 0 11.72 6.84 
IL13RA2 interleukin 13 receptor, alpha 2 613 9.26 0 0 11.71 2.45 
MAFF 
v-maf musculoaponeurotic 
fibrosarcoma oncogene F  28 4.82 0 0 11.66 6.84 
EIF5 eukaryotic translation initiation 5 38 5.25 0 0 11.65 6.39 
BCL10 B-cell CLL/lymphoma 10 487 8.93 0 0 11.64 2.72 
EDN1 endothelin 1 20 4.33 0 0 11.49 7.16 
KRTAP3-2 keratin associated protein 3-2 567 9.15 0 0 11.42 2.27 
ACTB actin, beta 32 5.02 0 0 11.41 6.39 
CXCL2 GRO2 Oncogene 323 8.33 0 0 11.36 3.03 
CHD2 
chromodomain helicase         
DNA binding protein 2 36 5.18 0 0 11.30 6.12 
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f
d
r FACS LCM 
IL1R2 interleukin 1 receptor, type II 31 4.96 0 0 11.30 6.34 
SGMS2 sphingomyelin synthase 2 173 7.43 0 0 11.18 3.75 
CD83 CD83 molecule 52 5.71 0 0 11.04 5.34 
CXCL3 GRO3 oncogene 123 6.94 0 0 10.71 3.77 
IRAK2 IL-1 receptor-associated kinase 2 25 4.62 0 0 10.54 5.92 
RBBP6 retinoblastoma binding protein 6 8 2.96 0 0 10.53 7.57 
CXCR4 chemokine receptor 4 176 7.46 0 0 10.43 2.97 
ANXA1 annexin A1 96 6.59 0 0 10.26 3.67 
IL6ST 
IL6 signal transducer    
(oncostatin M receptor) 28 4.78 0 0 10.24 5.46 
MCL1 
myeloid cell leukemia sequence 1 
(BCL2-related) 24 4.61 0 0 10.24 5.63 
FST follistatin 208 7.70 0 0 10.18 2.48 
HSPA13 heat shock protein 70kDa, 13 62 5.96 0 0 10.12 4.16 
PDK4 pyruvate dehydrogenase kinase, 4 11 3.44 0 0 10.08 6.64 
KRTAP19-1 keratin associated protein 19-1 202 7.66 0 0 9.97 2.32 
S100P S100 calcium binding protein P 34 5.07 0 0 9.82 4.75 
EGR4 early growth response 4 178 7.48 0 0 9.77 2.29 
IRF1 interferon regulatory factor 1 32 5.02 0 0 9.75 4.74 
CD44 CD44 molecule  107 6.74 0 0 9.55 2.82 
SPRR3 small proline-rich protein 3 25 4.63 0 0 9.55 4.91 
SOCS3 suppressor of cytokine signaling 3 33 5.02 0 0 9.48 4.45 
KLF7 Kruppel-like factor 7 (ubiquitous) 62 5.95 0 0 9.36 3.41 
MICB 
MHC class I polypeptide-related 
sequence B 48 5.60 0 0 9.28 3.68 
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Symbol Description FC log2FC  P 
f
d
r FACS LCM 
TSLP thymic stromal lymphopoietin 43 5.44 0 0 9.11 3.67 
TNFRSF21 tumor necrosis factor receptor 21 40 5.33 0 0 9.10 3.77 
EGR1 early growth response 1 46 5.54 0 0 9.10 3.56 
SOCS2 suppressor of cytokine signaling 2 48 5.58 0 0 9.03 3.45 
TNC tenascin C 45 5.48 0 0 9.01 3.53 
INHBA inhibin, beta A 95 6.58 0 0 9.00 2.43 
TGFB2 transforming growth factor ß 2 96 6.58 0 0 8.97 2.39 
OCLN occludin 30 4.90 0 0 8.87 3.97 
CEACAM1 
carcinoembryonic antigen-related 
cell adhesion molecule 1  87 6.44 0 0 8.82 2.38 
CXCL1 
chemokine ligand 1 (melanoma 
growth stimulating activity,α) 59 5.89 0 0 8.78 2.89 
GADD45G 
growth arrest and DNA-   
damage-inducible, gamma 6 2.59 0 0 8.78 6.19 
PI3 peptidase inhibitor 3, skin-derived 36 5.15 0 0 8.77 3.62 
TNFRSF10D 
TNF receptor superfamily10d, 
decoy w. truncated death domain 31 4.97 0 0 8.65 3.68 
EDNRB endothelin receptor type B 9 3.12 0 0 8.59 5.47 
HLA-F major histocompatibility class I, F 5 2.18 0 0 8.42 6.24 
G0S2 G0/G1switch 2 33 5.04 0 0 8.27 3.22 
RRAS2 related RAS oncogene homolog 2 28 4.81 0 0 7.99 3.18 
IL24 interleukin 24 30 4.93 0 0 7.73 2.80 
ELF3 
E74-like factor 3 (ets domain TF, 
epithelial-specific ) 33 5.06 0 0 7.71 2.65 
CDC23 cell division cycle 23 homolog  27 4.73 0 0 7.71 2.98 
ITGA5 integrin, α5; fibronectin receptor 22 4.48 0 0 7.61 3.14 
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Symbol Description FC log2FC  P 
f
d
r FACS LCM 
MAP3K8 mitogen-activated protein KKK 8 5 2.28 0 0 7.33 5.05 
NRG1 neuregulin 1 26 4.69 0 0 7.33 2.64 
HIST1H2AE histone cluster 1, H2ae 26 4.72 0 0 7.31 2.59 
TACSTD2 tumor-assoc signal transducer 2 27 4.78 0 0 7.27 2.50 
PTHLH parathyroid hormone-like  26 4.71 0 0 7.05 2.34 
ABL2 v-abl oncogene homolog 2  25 4.65 0 0 6.97 2.32 
TNF tumor necrosis factor  26 4.69 0 0 6.96 2.26 
VNN1 vanin 1 21 4.40 0 0 6.94 2.54 
IL20 interleukin 20 22 4.47 0 0 6.77 2.30 
IL1A interleukin 1, alpha 19 4.22 0 0 6.71 2.49 
KRT75 keratin 75 21 4.37 0 0 6.64 2.28 
VEGFC vascular endothelial G.F. C 20 4.30 0 0 6.57 2.27 
MET proto-oncogene (HGF receptor) 12 3.60 0 0 6.47 2.87 
FGFR1 fibroblast growth factor receptor1 13 3.72 0 0 6.17 2.45 
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The following table 7. Shows genes that are significantly up-regulated in 
keratinocytes obtained by FACS as compared to cultures in vitro.  In addition LCM 
values are listed [in grey.]  From this list of genes one can appreciate which alterations in 
gene expression are due to artifacts of culture as opposed to early activation genes 
triggered by disassociation and short term ex vivo incubation.  The LCM epidermal 
values are included to allow the reader the opportunity to appreciate the effect of 
inflammatory activation due to FACS methodology as compared to long or short-term 
culture ‘homeostasis’, as there are many genes whose expression vary vastly from the in 
situ to the ex vivo and in vitro environments. 
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Table 7.  Genes upregulated in FACS keratinocytes compared to in vitro cultured 
P-value cut-off of 0.01   Log2 of Fold Change>4            false discovery rate (fdr) 
 
Symbol Description FC log2FC P 
f
d
r 
in 
vitro FACS LCM 
CCL20 chemokine ligand 20 390 8.61 0 0 5.15 13.76 2.86 
IL13RA2 IL13 receptor, alpha 2 117 6.88 0 0 4.84 11.71 2.45 
IL8 interleukin 8 55 5.79 0 0 7.56 13.35 2.38 
CXCL2 chemokine ligand 2 36 5.17 0 0 6.19 11.36 3.03 
SGMS2 sphingomyelin synthase2 19 4.22 0 0 6.96 11.18 3.75 
MMP1 matrix metallopeptidase1  15 3.88 0 0 9.75 13.63 2.66 
PMAIP1 
phorbol-12-myristate-13-
acetate-induced protein 1 14 3.84 0 0 9.75 13.59 6.91 
TNFAIP3 
tumor necrosis factor, 
alpha-induced protein 3 12 3.64 0 0 9.32 12.96 6.35 
HBEGF 
heparin-binding EGF-
like growth factor 12 3.59 0 0 9.10 12.69 4.70 
TGFB2 TGF, beta 2 12 3.55 0 0 5.42 8.97 2.39 
CD44 CD44 molecule  11 3.47 0 0 6.09 9.55 2.82 
NFIL3 nuclear factor, IL3 reg’d 10 3.32 0 0 8.81 12.13 6.46 
PLAUR 
plasminogen activator, 
urokinase receptor 9 3.17 0 0 9.36 12.53 2.95 
IL7R interleukin 7 receptor 9 3.17 0 0 5.49 8.66 3.13 
SOD2 
superoxide dismutase 2, 
mitochondrial 8 2.93 0 0 9.33 12.25 6.63 
OSMR oncostatin M receptor 7 2.88 0 0 7.48 10.37 4.83 
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Symbol Description FC log2FC P 
f
d
r 
in 
vitro FACS LCM 
NEDD4L 
neural precursor cell 
expressed, 
developmentally down-
regulated 4-like 7 2.87 0 0 8.77 11.65 3.13 
GPRC5A 
G protein-coupled 
receptor, family C, group 
5, member A 7 2.86 0 0 9.25 12.11 2.58 
HIST1H4B histone cluster 1, H4b 7 2.83 0 0 5.99 8.82 3.24 
FOSL1 FOS-like antigen 1 7 2.78 0 0 9.29 12.07 2.93 
JUN jun oncogene 7 2.72 0 0 10.71 13.43 6.46 
NEDD9 
neural precursor cell, 
developmentally down-
regulated 9 7 2.71 0 0 5.87 8.59 3.75 
IL24 interleukin 24 6 2.70 0 0 5.03 7.73 2.80 
SESN2 sestrin 2 6 2.64 0 0 7.54 10.18 4.86 
CFLAR 
CASP8 and FADD-like 
apoptosis regulator 5 2.44 0 0 8.35 10.79 6.36 
ADM adrenomedullin 5 2.31 0 0 11.51 13.82 9.17 
CTTN cortactin 5 2.29 0 0 8.67 10.96 6.43 
CREB5 
cAMP responsive 
element binding protein 5 5 2.24 0 0 6.78 9.01 4.48 
FOXC1 forkhead box C1 5 2.21 0 0 9.83 12.04 4.69 
TMEFF1 
transmembrane w. EGF-
like & follistatin-like 1 4 2.16 0 0 6.57 8.73 2.62 
SYNJ2 synaptojanin 2 4 2.14 0 0 6.46 8.61 4.21 
JMJD6 jumonji domain 6 4 1.98 0 0 8.26 10.23 5.78 
ERRFI1 
ERBB receptor feedback 
inhibitor 1 4 1.91 0 0 12.09 14.00 10.06 
TLE1 transducinlike enhancer1  4 1.82 0 0 8.20 10.03 5.31 
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Symbol Description FC log2FC P 
f
d
r 
in 
vitro FACS LCM 
KPNA4 karyopherin alpha 4  3 1.75 0 0 7.82 9.57 5.19 
PATL1 
protein assoc with 
topoisomerase II 1  3 1.73 0 0 5.18 6.91 2.85 
SOX9 SRY box 9 3 1.68 0 0 8.60 10.28 2.99 
PCOLCE2 
procollagen C-
endopeptidase enhancer 2 3 1.65 0 0 6.10 7.75 2.99 
MCL1 
myeloid cell leukemia 
seq1 (BCL2-related) 3 1.63 0 0 8.60 10.24 5.63 
EIF5 
eukaryotic translation 
initiation factor 5 3 1.54 0 0 10.10 11.65 6.39 
CDC23 cell division cycle 23  3 1.48 0 0 6.23 7.71 2.98 
NEU1 sialidase 1 (lysosomal) 3 1.47 0 0 7.90 9.37 5.42 
RAP2B RAS oncogene family 3 1.43 0 0 6.75 8.18 4.21 
HIC2 
hypermethylated in 
cancer 2 3 1.43 0 0 7.79 9.22 5.20 
DNAJA1 DnaJ (Hsp40)A,member1 3 1.40 0 0 11.73 13.13 9.33 
S100A9 S100 calcium b.p. A9 3 1.39 0 0 11.26 12.65 5.10 
IRF6 IFN regulatory factor 6 3 1.37 0 0 10.96 12.33 7.57 
CDKN1A 
cyclin-dependent kinase 
inhibitor 1A (p21, Cip1) 3 1.36 0 0 12.13 13.49 9.54 
HSPA13 
heat shock protein 70kDa 
family, member 13 3 1.33 0 0 7.72 9.05 5.33 
CD164 
CD164 molecule, 
sialomucin 2 1.29 0 0 7.94 9.23 5.69 
KPNA1 
karyopherin alpha 1 
(importin alpha 5) 2 1.20 0 0 6.18 7.38 3.09 
HIST1H2BK histone cluster 1, H2bk 2 1.19 0 0 10.60 11.79 8.29 
HIST1H2BC histone cluster 1, H2bc 2 1.19 0 0 6.36 7.55 3.72 
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Symbol Description FC log2FC P 
f
d
r 
in 
vitro FACS LCM 
CLU clusterin 2 1.18 0 0 7.71 8.89 5.72 
LCE3D late cornified envelope  2 1.16 0 0 12.40 13.55 9.50 
FGD6 
FYVE, RhoGEF and PH 
domain containing 6 2 1.10 0 0 8.60 9.70 5.93 
PVRL2 
poliovirus receptor-
related 2 (herpesvirus B) 2 1.10 0 0 6.41 7.51 4.31 
SOCS2 suppressor of cyt sig 2 2 1.10 0 0 7.93 9.03 3.45 
CCNE1 cyclin E1 2 1.09 0 0 7.89 8.98 5.35 
KIAA1949 KIAA1949 2 1.04 0 0 8.77 9.80 5.13 
VEGFA vascular endothelial GFA 2 1.04 0 0 8.46 9.49 6.46 
MAP7D1 MAP7 domain contain1 2 1.03 0 0 9.17 10.21 6.47 
TGIF1 
TGFB-induced factor 
homeobox 1 2 1.03 0 0 9.79 10.82 7.32 
PGF placental growth factor 2 0.96 0 0 7.06 8.02 4.39 
TOB1 transducer of ERBB2, 1 2 0.93 0 0 12.55 13.49 10.27 
ETS1 
v-ets erythroblastosis 
virus E26 oncogene 1  2 0.93 0 0 12.55 13.48 9.08 
PRNP prion protein 2 0.90 0 0 6.09 6.99 3.43 
GADD45A 
growth arrest and DNA-
damage-inducible, alpha 2 0.89 0 0 12.31 13.21 8.57 
BAIAP2L1 BAI1-assoc 2-like 1 2 0.87 0 0 8.40 9.27 4.80 
DDIT4 DNAdamage-inducible 4 2 0.87 0 0 11.64 12.51 7.55 
OSBPL10 oxysterol b.p.-like 10 2 0.86 0 0 4.68 5.54 2.43 
NFATC2IP 
NF of activated T-cells, 
cytoplasmic, calcineurin-
dependent 2 interacting  2 0.84 0 0 8.72 9.56 6.64 
CD47 CD47 molecule 2 0.84 0 0 10.20 11.04 7.47 
 
 
73 
Symbol Description FC log2FC P 
f
d
r 
in 
vitro FACS LCM 
HSPH1 
heat shock 105kDa 
/110kDa protein 1 2 0.80 0 0 11.78 12.58 8.63 
SMAD7 SMAD family member 7 2 0.79 0 0 7.15 7.94 4.96 
UCA1 
urothelial cancer 
associated 1  2 0.78 0 0 5.14 5.92 2.55 
GMFB glia maturation factor, β 2 0.77 0 0 10.07 10.84 6.64 
H2BFS H2B histone, member S 2 0.77 0 0 7.95 8.71 4.68 
PMEPA1 
prostate TM protein, 
androgen induced 1 2 0.75 0 0 10.43 11.18 4.50 
ARHGEF2 Rho/Rac (GEF) 2 2 0.74 0 0 9.63 10.37 6.20 
TRIP10 
thyroid hormone receptor 
interactor 10 2 0.73 0 0 7.20 7.93 4.79 
EIF4E 
eukaryotic translation 
initiation factor 4E 2 0.71 0 0 9.75 10.46 6.32 
STIP1 
stress-induced-
phosphoprotein 1 2 0.70 0 0 4.89 5.59 2.74 
ANXA1 annexin A1 2 0.70 0 0 13.92 14.62 11.25 
CANX calnexin 2 0.69 0 0 9.43 10.12 5.99 
CXCL1 
melanoma growth 
stimulating activity α 2 0.68 0 0 8.11 8.78 2.89 
TNFRSF10D 
TNF receptor, 10d, decoy  
truncated death domain 2 0.68 0 0 7.98 8.65 3.68 
ABL2 
v-abl murine leukemia 
oncogene homolog 2  2 0.64 0 0 8.55 9.19 5.92 
S100A8 S100 calcium b.p. A8 2 0.64 0 0 13.56 14.20 7.19 
PDS5A 
PDS5, regulator of 
cohesion maintenance, A  2 0.60 0 0 8.45 9.05 5.26 
NRAS 
neuroblastoma RAS viral 
oncogene homolog 1 0.58 0 0 8.87 9.45 5.49 
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Symbol Description FC log2FC P 
f
d
r 
in 
vitro FACS LCM 
ROD1 
ROD1 regulator of 
differentiation 1  1 0.57 0 0 9.00 9.56 6.87 
MED21 mediator complex 21 1 0.56 0 0 7.75 8.31 5.46 
TNC tenascin C 1 0.53 0 0 8.48 9.01 3.53 
DSC2 desmocollin 2 1 0.53 0 0 9.50 10.03 5.72 
G2E3 
G2/M-phase specific E3 
ubiquitin ligase 1 0.52 0 0 6.67 7.20 4.67 
PEX13 
peroxisomal biogenesis 
factor 13 1 0.52 0 0 7.18 7.70 5.14 
DSG3 desmoglein 3  1 0.49 0 0 10.33 10.82 4.96 
LPIN1 lipin 1 1 0.49 0 0 8.94 9.43 5.68 
MPZL2 myelin protein zero-like2 1 0.48 0 0 7.00 7.48 3.57 
CCNYL1 cyclin Y-like 1 1 0.47 0 0 7.62 8.09 3.61 
PLK2 polo-like kinase 2  1 0.47 0 0 12.55 13.02 10.55 
ILF2 IL enhancer factor 2 1 0.44 0 0 10.10 10.55 7.22 
PGRMC1 
progesterone receptor 
membrane component 1 1 0.44 0 0 6.16 6.60 3.82 
MAP4K4 
mitogen-activated protein 
kinase kinase kinase 
kinase 4 1 0.44 0 0 6.76 7.20 3.69 
GLS glutaminase 1 0.41 0 0 6.70 7.11 3.11 
TNFRSF12A TNF receptor, 12A 1 0.36 0 0 10.62 10.98 4.59 
AKT3 
v-akt murine thymoma 
oncogene homolog 3  1 0.35 0 0 5.04 5.39 2.88 
TGFA TGF alpha 1 0.34 0 0 11.38 11.72 7.68 
CDK2AP2 
cyclin-dependent kinase 
2 associated protein 2 1 0.33 0 0 7.85 8.18 5.00 
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Symbol Description FC log2FC P 
f
d
r 
in 
vitro FACS LCM 
CDYL 
chromodomain protein, 
Y-like 1 0.32 0 0 8.07 8.39 6.06 
IER3 Immediate early response  1 0.32 0 0 13.71 14.03 10.48 
GRB10 g.f. receptor-b.p. 10 1 0.29 0 0 7.23 7.52 4.14 
FGG fibrinogen gamma chain 1 0.29 0 0 11.06 11.35 8.96 
ZAK zipper kinase AZK 1 0.29 0 0 10.19 10.47 7.93 
HIST1H2BD histone cluster 1, H2bd 1 0.27 0 0 8.95 9.22 6.66 
MAP2K1 
mitogen-activated protein 
kinase kinase 1 1 0.25 0 0 9.56 9.81 6.49 
HUS1 HUS1 checkpoint  1 0.24 0 0 8.14 8.38 5.66 
SYPL1 synaptophysin-like 1 1 0.24 0 0 8.81 9.05 5.67 
PAK2 
p21 protein (Cdc42/Rac)-
activated kinase 2 1 0.23 0 0 7.28 7.51 3.91 
MAOA monoamine oxidase A 1 0.23 0 0 9.70 9.93 7.01 
ANXA5 annexin A5 1 0.19 0 0 12.08 12.27 9.84 
PNLIPRP3 
pancreatic lipase-related 
protein 3 1 0.19 0 0 11.73 11.92 4.78 
STAT3 acute-phase response fac 1 0.18 0 0 7.35 7.53 3.59 
CKS2 
CDC28 protein kinase 
regulatory subunit 2 1 0.17 0 0 11.47 11.64 8.68 
RABL3 RAS oncogene -like 3 1 0.15 0 0 6.16 6.30 3.58 
TICAM2 TLR adaptor molecule 2 1 0.13 0 0 7.90 8.04 4.22 
MYO1B myosin IB 1 0.13 0 0 10.43 10.56 5.17 
MSN moesin 1 0.13 0 0 11.92 12.05 9.82 
TRAF4 TNF rec-assoc factor 4 1 0.12 0 0 7.86 7.98 5.17 
TCEB1 
transcription elongation 
factor B polypeptide 1  1 0.12 0 0 10.33 10.45 8.14 
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Symbol Description FC log2FC P 
f
d
r 
in 
vitro FACS LCM 
TNIP1 TNFAIP3 protein 1 1 0.11 0 0 11.54 11.65 9.18 
HMGA1 high mobility AT-hook 1 1 0.07 0 0 10.72 10.79 8.58 
CD59 complement regulatory  1 0.06 0 0 11.24 11.30 7.45 
CD24 CD24 molecule 1 0.05 0 0 9.56 9.61 5.31 
CTGF connective tissue G.F. 1 0.04 0 0 7.49 7.53 2.73 
MALT1 
mucosa associated 
lymphoma translocation1 1 0.02 0 0 9.08 9.11 6.43 
ARHGAP21 
Rho GTPase activating 
protein 21 1 0.02 0 0 10.16 10.18 7.29 
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This data is perhaps the most difficult to interpret; though, the ex vivo cells 
isolated by FACS were more similar to the in situ LCM samples than keratinocytes 
cultured in vitro, they have been taken out of their natural environment and processed to 
create a single cell suspension necessary for this technique. Regulation of gene 
expression in isolated keratinocytes was therefore affected by the mere methodology of 
dissociating cells from whole tissue and subsequent short-term incubation to restore 
surface antigen after enzymatic processing.    
Keratins 1 and 10, typically co-expressed in suprabasal terminally differentiated 
cells of epidermis, were seen at lowest levels in vitro and found at high levels in vivo 
especially from samples collected by LCM.  Keratin 2 has been shown to be associated 
with the upper spinous layer and was seen to be at low levels in in vitro culture.  CDK 
inhibitor 1B was also absent in keratinocytes in culture, showing negative regulation of 
cell proliferation only from samples collected most directly from tissue.   
Though we try to avoid dissecting hair follicles with the epidermis using LCM, 
they would obviously be absent from cells in culture, as was also seen in single-cell 
suspensions from FACS by the lack of Keratin 72 and Keratin 73 expression.  KRT75 
a.k.a. Keratin 6 is predominately seen in cells that have been induced to hyperproliferate 
by disease, injury, and in epithelial cell culture conditions; so, it is not a surprise to see its 
highest level in vitro and even some of the FACS samples that were incubated overnight.  
Ki-67 is commercially available to detect proliferating cells but not in quiescent ones.  
Expression of this antigen occurs preferentially during late G1, S, G2 and M phases of 
the cycle, but cannot be detected in those that have entered G0, which includes the 
majority of the cellular residents in normal epithelium.   
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Chapter 4. Comparison of Melanocyte vs. Langerhans cells by FACS 
 
Theory and aims 
In the previous chapter we examined genes expressed in cultured and FACS 
Keratinocytes, along with LCM epidermis, which showed a wide variability of 
expression depending on the conditions from which the cells were extracted.  In this part 
of the thesis the goal was to examine FACS samples of epidermal suspensions to 
establish melanocyte-selective genes.  It seemed necessary to extract melanocytes 
directly from human skin instead of using primary cell lines that had already been subject 
to exogenous mitogens.  The first aim was to segregate the major cell types of the 
epidermis: keratinocytes from the morphologically dendritic melanocyte and Langerhans 
cells.  
It has been widely accepted that c-kit is present on melanocytes, necessary during 
embryogenesis for proper migration of melanoblasts from the neural crest and subsequent 
differentiation.  Though typically associated with B cells, published literature and 
staining of c-kit in mice and humans demonstrates a strong co-stain with melanocytes, 
especially robust in hair follicle sheaths.  I therefore hypothesized that the antibody to 
this surface membrane receptor could isolate melanocytes from the epidermis using 
FACS.  Figure 2 is an illustration of the staining of c-kit in skin from our lab.  In a 
collaborative effort with Dr. Hideki Fujita, who studies Langerhans cells, the dendritic 
cell population in the epidermis, we were able to use the same skin samples sorting for c-
kit or Langerin (the CD207 antigen) from the epidermis.  In this manner we were able to 
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get the cells necessary for our respective experiments, as well as verifying each others’ 
data.    
Prior to analyzing the cells obtained for genomics, it was pertinent to establish 
that they were in fact accurately isolated by this novel technique.  Thus, the two 
populations of cells that make up the minority of the epidermis, CD1a+/CD207+ 
Langerhans cells & CD117+ melanocytes, were compared and scrutinized for their 
characteristic gene expression.  We decided that this was an acceptable protocol for 
isolating melanocytes, as typical cell-specific genes were present, including many of the 
enzymes from the pigmentation pathway that are lost in culture.  In addition, the CD207+ 
population contained many of the gnomic markers of Langerhans cell including HLA and 
other dendritic cell genes, further confirming the methodology. 
It is of note that subsequently, another group reported the used of antibodies to c-
kit to isolate murine melanocytes from mixed dermal cell suspensions (murine 
melanocytes are follicular and not epidermal.)  Their determination that these cells were 
indeed melanocytes serves to validate this technique; but, their methods, however, 
included 10 days of in vitro culture prior to FACS in media containing FBS, bFGF, PMA 
and transferrin among other undefined elements in exogenous media [89].  Their 
resulting primary cell population is therefore more akin to the commercial PromoCell 
primary cells used in our work, with several additional mitogenic effects in their 
melanocyte growth medium. 
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Figure 2.  20x image of c-kit staining human skin.  Staining is seen primarily in the 
basal cell layer of the epidermis, though some mast cells etc are also stained in the dermis 
(though this layer is removed prior to cell suspension for staining and FACS.) 
Picture courtesy of Hiroshi Mitsui, M.D., Ph.D. 
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Figure 3.  FACS single positive populations of CD117+ (c-kit) melanocytes and  
      CD207+ Langerhans cells were used for analysis in this chapter. 
 
Collaboration with Hideki Fujita, M.D., Ph.D. 
 
Langerhans cell populations 
 Upon inspection of the top 80 genes differentially expressed from the CD1a+ 
partition, as compared to the CD117+ population, one can be confident that they are 
indeed Langerhans cells.  They expressed to the highest degree the lysosomal-associated 
membrane protein 3, otherwise known as DC-LAMP.  Indoleamine-pyrrole 2,3 
dioxygenase (INDO,) which is an immunomodulating tryptophan-catabolizing enzyme, 
was also among this highly expressed group of genes unique to dendritic cells of the skin.  
Other surface molecules detected at elevated levels include the major histocompatibility 
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complexes HLA-DQalpha1 and HLA-DQbeta1, CD86, CD205 (LY75,) CCR7 and 
colony-stimulating factor 2 receptor alpha (CSF2RA.)  Inflammatory chemokine IL-1β 
was also expressed.  Prostaglandin receptor EP4 (PTGER4) is essential for migration of 
Langerhans cells to regional lymph nodes in mice [90].  Ten genes highly expressed in 
the CD117+ population representative of Langerhans cells are shown in Table 8. 
 
Table 8.  Langerhans genes highly expressed in FACS-derived populations 
Fold 
change 
(LC - Mel) Gene Symbol Gene Title 
522 LAMP3 lysosomal-associated membrane protein 3 
419 CCR7 chemokine (C-C motif) receptor 7 
358 INDO indoleamine-pyrrole 2,3 dioxygenase 
207 HLA-DQA1 major histocompatibility complex, class II, DQ α1 
170 CSF2RA  colony stimulating factor 2 receptor, alpha,  
167 CD86 CD86 molecule 
153 HLA-DQA1 major histocompatibility complex, class II, DQ α1 
149 PTGER4 prostaglandin E receptor 4 (subtype EP4) 
103 LY75 lymphocyte antigen 75 
85 IL1B interleukin 1, beta 
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Melanocyte cell populations 
 What is most interesting and exciting upon examination of the top 100, shown in 
table 9, differentially expressed transcripts in the c-kit+ pool is how many unknown and 
hypothetical proteins were identified, because these represent novel, putative melanocyte-
specific genes.  At the top of the list is TRPM1, also known as melastatin-1, a relatively 
novel gene that seems to correlate directly with melanin content.  Typical melanocyte-
associated genes such as melan-A and tyrosinase are increased by 23-fold relative to the 
Langerhans cell isolate.  N.B. there may be some genes represented more than once, due 
to the array technique which has several probes per gene, duplication is only further 
verification that the gene is truly expressed and was accurately detected.. The detection of 
preciously reported melanocyte-specific genes further indicted the successful isolation of 
melanocyte by this method. 
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Table 9.  Top 100 Genes expressed in Melanocytes as compared to Langerhans cells 
 
 
Fold 
Change 
(M-LC) Gene Symbol Gene Title 
98 TRPM1 transient receptor potential cation channel subfamily M,1 
83 LOC100129562 hypothetical protein LOC100129562 
78 BCHE butyrylcholinesterase 
69 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 
69  CDNA clone IMAGE:4791597 
66  CDNA clone IMAGE:4791597 
63  Transcribed locus 
61  CDNA clone IMAGE:5311370 
57 GPM6B glycoprotein M6B 
53 PAX3 paired box 3 
53 PCSK2 proprotein convertase subtilisin/kexin type 2 
49 GMPR guanosine monophosphate reductase 
49 SGCE sarcoglycan, epsilon 
49  Transcribed locus 
48 SLC6A15 solute carrier family 6, member 15 
44 SRPX sushi-repeat-containing protein, X-linked 
44  Transcribed locus 
42 LPPR4 plasticity related gene 1 
42 GPM6B glycoprotein M6B 
42 ASPA aspartoacylase (Canavan disease) 
41 ZNF521 zinc finger protein 521 
41 GPR155 G protein-coupled receptor 155 
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Fold 
Change 
(M-LC) Gene Symbol Gene Title 
41 EPHA5 EPH receptor A5 
39 SORBS2 sorbin and SH3 domain containing 2 
38 PDE10A phosphodiesterase 10A 
38 SPARC secreted protein, acidic, cysteine-rich (osteonectin) 
38 LZTS1 leucine zipper, putative tumor suppressor 1 
37 STXBP6 syntaxin binding protein 6 (amisyn) 
36 LOC493869 Similar to RIKEN cDNA 2310016C16 
36  Homo sapiens, clone IMAGE:4214654, mRNA 
36 RHOBTB3 Rho-related BTB domain containing 3 
36 CDH19 cadherin 19, type 2 
36 GYG2 glycogenin 2 
36 TRIM2 tripartite motif-containing 2 
35 PLSCR4 phospholipid scramblase 4 
34 PAG1 phosphoprotein associated with glycosphingolipid 1 
34 TRPM1 transient receptor potential cation channel subfamily M,1 
34 CSPG4 chondroitin sulfate proteoglycan 4 
34 SORBS1 sorbin and SH3 domain containing 1 
34 TRIM63 tripartite motif-containing 63 
33 TFAP2B transcription factor AP-2 beta  
33 CAPN3 calpain 3, (p94) 
33 GPM6B glycoprotein M6B 
32 PPP1R9A protein phosphatase 1, regulatory (inhibitor) subunit 9A 
32  MRNA from chromosome 5q31-33 region 
32  CDNA FLJ39330 fis, clone OCBBF2016405 
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Fold 
Change 
(M-LC) Gene Symbol Gene Title 
32 DPP6 dipeptidyl-peptidase 6 
32 AEBP1 AE binding protein 1 
31 VEPH1 ventricular zone expressed PH domain homolog 1  
31 TIMP2 TIMP metallopeptidase inhibitor 2 
31 RHOJ ras homolog gene family, member J 
31 GPM6B glycoprotein M6B 
31  CDNA FLJ90705 fis, clone PLACE1007591 
31 SPTBN1 spectrin, beta, non-erythrocytic 1 
30 PKNOX2 PBX/knotted 1 homeobox 2 
30 TBC1D16 TBC1 domain family, member 16 
30  Homo sapiens, clone IMAGE:3618365, mRNA 
30 DIP2C DIP2 disco-interacting protein 2 homolog C (Drosophila) 
29  MRNA, clone ICRFp507B0451 
29  Transcribed locus 
29 CABLES1 Cdk5 and Abl enzyme substrate 1 
29 C6orf218 Chromosome 6 open reading frame 218 
28 DLC1 deleted in liver cancer 1 
28 SLC6A15 solute carrier family 6, member 15 
28 MAP1B microtubule-associated protein 1B 
28  CDNA clone IMAGE:5284125 
27 LEF1 lymphoid enhancer-binding factor 1 
27  Transcribed locus 
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Chapter 5.  FACS Melanocytes vs. Melanocyte lines in culture 
 
Theory and aims 
After showing how many alterations accumulate in culture with keratinocytes it 
was even more pertinent to examine melanocytes, as they do not replicate under non-
pathologic conditions, and therefore in vitro models are likely to be extremely 
misleading.  Melanocytes can progress to different types of dysplasia, including nevi, 
dysplastic nevi and lentigo simplex.  In turn, these can develop into melanoma in situ or 
lentigo maligna which then may have migratory potential and become invasive malignant 
melanoma. It is therefore pertinent for pathology to discover which growth pathways 
allow melanocytes to proliferate, even if only transiently (eg BRAF expressed 
transitorily.)  If a growth factor or growth-regulated pathway identified in resting 
melanocytes that trigger the non-proliferative cells to grow, then the question arises as to 
what is the dependence of melanoma on such pathways.  Is there a growth addiction or do 
they become superfluous?  Looking at in vitro cultured melanocytes may show what the 
genomic pathways are that underlie conversion from hyperplasia to neoplasia.  
 Preparations of ten FACS melanocytes were compared with 12 NHEM 
established in serum-free culture using gene array.  Some of the genes in the FACS were 
due to some keratinocyte contamination that could be removed by additional 
computational subtraction, but are included here as they are an artifact inherrant to the 
FACS technique. 
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Results 
 The two sources of melanocytes differed especially in cell-cycle related genes (as 
shown in tables 10a and 10b,) but the typical pigmentation genes were not differentially 
expressed.  Table 11 shows some pigmentation related genes and many melanosome 
genes were detected at high levels in vitro as compared to FACS. 
 
Table 10a.  Genes expressed at high levels in c-kit+ FACS Melanocytes as compared               
           to 1°  Melanocytes cells in vitro (probable role in cell proliferation.) 
 
 
Symbol Description FC log2FC P fdr Vitro FACS 
FOS 
FBJ murine osteosarcoma 
viral oncogene homolog 17.29 4.11 0 0 6.02 10.13 
BCL2 B-cell CLL/lymphoma 2 9.90 3.31 0 0 8.14 11.45 
JUN jun oncogene 8.99 3.17 0 0 7.84 11.01 
FGF9 
fibroblast growth factor 9 
(glia-activating factor) 8.93 3.16 0 0 2.27 5.43 
EDN1 endothelin 1 8.48 3.08 0 0 2.34 5.42 
PIK3CA 
phosphoinositide-3-kinase, 
catalytic, alpha  8.40 3.07 0 0 4.38 7.45 
KRAS 
v-Ki-ras2 rat sarcoma viral 
oncogene homolog 6.36 2.67 0 0 2.34 5.01 
RAF1 
v-raf-1 murine leukemia viral 
oncogene homolog 1 6.35 2.67 0 0 4.62 7.29 
PTEN 
phosphatase and tensin 
homolog 5.17 2.37 0 0 4.37 6.74 
MAPK8 
mitogen-activated protein 
kinase 8 4.01 2.00 0 0 4.92 6.92 
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Table 10b.  Genes expressed in 1°  Normal Human Melanocytes cells in vitro             
as compared to c-kit+ FACS Melanocytes (probable role in cell proliferation.) 
 
 
Symbol Description FC log2FC P fdr 
in 
vitro FACS 
BAX BCL2-associated X protein 78 6.28 0 0 10.44 4.16 
CRK 
v-crk sarcoma virus CT10 
oncogene homolog (avian) 46 5.51 0 0 8.32 2.81 
CDC2 
cell division cycle 2, G1 to S and 
G2 to M 29 4.85 0 0 7.80 2.95 
IGF2R 
insulin-like growth factor 2 
receptor 29 4.85 0 0 9.73 4.88 
TOP2A 
topoisomerase (DNA) II alpha 
170kDa 22 4.46 0 0 7.74 3.28 
TP53I3 
tumor protein p53 inducible 
protein 3 19 4.25 0 0 9.71 5.46 
MCF2 
MCF.2 cell line derived 
transforming sequence 19 4.25 0 0 6.65 2.41 
MAP2K2 MAPK kinase 2 19 4.23 0 0 7.30 3.07 
CCNB2 cyclin B2 17 4.06 0 0 7.66 3.60 
RAC1 ras-related C3 botox substrate 1  16 3.97 0 0 10.93 6.96 
CDK2 cyclin-dependent kinase 2 15 3.88 0 0 8.00 4.12 
MET 
met proto-oncogene (hepatocyte 
growth factor receptor) 11 3.45 0 0 10.83 7.38 
FGFR1 fibroblast growth factor receptor  8 2.93 0 0 11.23 8.29 
AKT1 
v-akt murine thymoma viral 
oncogene homolog 1 6 2.67 0 0 9.68 7.01 
BRCA1 breast cancer 1, early onset 6 2.67 0 0 8.81 6.14 
STAT3  (acute-phase response factor) 6 2.49 0 0 8.86 6.37 
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Table 11.   
Melanocyte-associated genes up-regulated in vitro over c-kit+ FACS (P<0.01)  
 
Symbol Description log2FC FC P fdr 
in 
vitro FACS 
ABCB5 ATP-binding cassette 5 9.33 645 0 0 12.25 2.92 
SLC45A2 solute carrier fam 45, 2 5.67 51 0 0 9.43 3.76 
GNAQ 
guanine nucleotide b.p.(G 
protein), q polypeptide 5.33 40 0 0 9.98 4.65 
PPIB 
peptidylprolyl isomerase B 
(cyclophilin B) 4.53 23 0 0 12.78 8.25 
RAB5C RAS oncogene family 4.39 21 0 0 10.47 6.08 
YWHAZ 
tyrosine 3-
monooxygenase/tryptophan 
5-monooxygenase 
activation protein, zeta  4.20 18 0 0 10.70 6.50 
PLDN pallidin homolog (mouse) 4.15 18 0 0 8.46 4.32 
GANAB glucosidase, alpha; AB 4.11 17 0 0 10.44 6.33 
SERPINF1 
serpin peptidase inhibitor, 
clade F (alpha-2 
antiplasmin, pigment 
epithelium derived factor), 
member 1 4.08 17 0.001 0 11.66 7.58 
CALU calumenin 4.01 16 0 0 8.68 4.67 
DDT D-dopachrome tautomerase 3.92 15 0 0 10.26 6.34 
LAMP1 
lysosomal-associated 
membrane protein 1 3.91 15 0 0 7.04 3.13 
HSP90AB1 
heat shock protein 90kDa 
alpha (cytosolic), class B 1 3.86 15 0 0 10.99 7.13 
YWHAE 
tyrosine 3-
monooxygenase/tryptophan 
5-monooxygenase 
activation protein, epsilon  3.81 14 0 0 7.75 3.94 
MMP14 
matrix metallopeptidase 14 
(membrane-inserted) 3.77 14 0 0 8.05 4.28 
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Chapter 6. 
Using receptor information to investigate putative growth factors 
(and/or other new pathways not previously identified) 
 
Theory and aims 
A plethora of information regarding melanocyte growth factors have been 
published, but most accounts were derived from cells grown in undefined media.  It was 
thus necessary to determine which factors are necessary for melanocyte survival and 
proliferation in defined medium.  Results of initial genomic profiling of NHEM receptor 
expression as compared to the vast list of receptors indicated in silico as being essential 
in melanocyte growth in undefined media yielded an overlapping list of receptors that we 
aimed to target using specific ligands.  Our hypothesis being that each of the growth 
factors may be able to stimulate their receptor to independently promote proliferation of 
melanocytes.  Comparison of in vitro receptor expression with current methods of 
melanocytic culture in silico led to the consensus that there are at least 4 main growth 
factors may be needed for proper signaling: bFGF, HGF, SCF and ET-3.   
Basic fibroblast growth factor, also known as FGF2, is a wide-spectrum 
mitogenic, angiogenic, and neurotrophic factor that is expressed at low levels in many 
tissues and cell types and reaches high concentrations in the brain and pituitary gland. 
FGF2, or bFGF, has been implicated in a multitude of physiologic and pathologic 
processes, including limb development, angiogenesis, wound healing, and tumor growth. 
bFGF is important for melanocyte survival and is produced in the skin by keratinocytes 
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and fibroblasts.  While bFGF is not known to be expressed by normal melanocytes, it has 
been shown to be expressed by melanoma cells[91] acting via its specific transmembrane 
receptor (FGFR) and activating the subsequent intracellular second messenger cascades.  
The MET proto-oncogene encodes for the hepatocyte growth factor (HGF) 
receptor, a plasma membrane tyrosine kinase that is involved in melanocyte growth and 
melanoma development.  MET is expressed on melanocytes and HGF is a growth factor 
for cultured melanocytes [92].  HGF/MET has been shown to influence melanocyte 
transformation and the acquisition of the metastatic phenotype [93].  The role of MET in 
growth and motility, often called “invasive growth” places MET at a center stage of 
tumor and metastasis development. Indeed, MET overexpression is very common in 
human cancer.  
Stem cell factor (SCF), also known as steel factor or c-kit ligand, stimulates 
migration, proliferation, and differentiation of mouse melanocytes. Loss of SCF in mice 
leads to the absence of melanoblasts.[94] SCF is expressed in endothelial cells and 
keratinocytes but not frequently in basal melanocytes[95,96] and is highly mitogenic for 
human melanoblasts and melanocytes in culture and for melanocytes in vivo.[97,98]   
Among the major paracrine factors that are involved in melanocyte biology, the 
endothelins play significant roles during the early development of these cells, in their 
response to ultraviolet (UV) radiation, and in pathological conditions including 
melanoma.  A role for ET-3 as a survival and proliferation factor for committed 
precursors has been established in both avian and mouse models.  Waardenburg 
syndrome type 4 (WS4), or Shah-Waardenburg syndrome, is also known as Hirschsprung 
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disease Type II (HSCR II) and is characterized by an absence of epidermal melanocytes 
and enteric ganglia.  Mutations in the genes encoding the endothelin type-B receptor 
(EDNRB) and its physiological ligand endothelin 3 (ET-3) are now known to account for 
the majority of HSCR II patients.  Little is known about the mechanisms underlying the 
regulation of the endothelin receptor B (EDNRB) expression in melanocytes.  EDNRB 
and ET-3 are transiently expressed in crest-derived melanoblast and neuroblast 
precursors, and in the surrounding mesenchymal cells, respectively. The influence of 
EDNRB-mediated signaling on the emigration, migration, proliferation, and 
differentiation of melanocyte and enteric neuron precursors, in vivo and in vitro has 
recently been the subject of great scrutiny.  
There was then the need to create a defined media in which to examine different 
combinations of these growth factors at known concentrations minus the pituitary 
homogenate and serum typically present in vitro. We sought to establish mitogenic 
potential of single growth factors and also combinations thereof in defined 
medium.Hence, individual and synergistic effects of growth factors bFGF, HGF, SCF 
and ET-3 were determined on melanocytes cultured in defined medium. 
 
Results 
Conventional methods of cell proliferation are not readily adaptable to assessing 
melanocyte growth as the primary cells are quite delicate, so any staining protocols such 
as CFSE labeling had to be vastly modified, ie reducing incubation time and 
concentration of dye used.  In addition, melanocytes in vivo do not replicate under non-
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pathologic conditions, hence doubling time in vitro is around three days.  Some of the 
defined media conditions (eg basal media alone) do not support cell survival let alone 
proliferation.  Simple methods of cell counts amongst growth media conditions only 
show changes in survival, and therefore do not give clear or absolute information 
pertaining to growth signals.  Kits such as those sold by Invitrogen are often subject to 
variation in metabolism and thus could not be relied upon for this particular assay.   
Melanocytes were highly influenced by the different media, as visualized by 
microscopic analysis of cell morphology, but cell number counts alone cannot distinguish 
between simple survival in vitro and withdrawal from active proliferation.  It was clear 
that different conditions of growth factors and combinations thereof did indeed affect 
growth, but in the search for “normal”, distinct changes in morphology that accompanied 
growth precluded the use of raw cell counts alone.  Figure 5 includes photographic 
examples of primary human melanocytes in the various defined culture medium 
conditions as well as brief descriptive analysis of growth and morphology after one cell 
doubling (3 days) in Table 12.   As melanocyte medias are proprietary, the documentation 
of the pure effects of individual growth factor on cell survival in vitro is novel.  
 
 
 
 
 
 
 
95 
Table 12.  
Defined Media conditions for 1°  Melanocyte & description after 3 days in vitro 
 
  
 Insulin HC FGF HGF SCF ET3 Visual description by microscopy 
1             many dead cells, some spread 
2             survival, bi-polar cells; senescent ? 
3             survival; similar to 2  
4             proliferation is marked; similar to 3  
5             proliferation is marked  
6             very short bipoles; survival questionable 
7             not as good as 3; shorter bipoles 
8             proliferation is marked  ≅ 3 (and 5) 
9             proliferation is marked; better than 3  
10             very short bipoles, less growth than 9 
11             short/intermediate bipoles, growth<9 
12             growth with abundance of short bipoles 
13             growth=9, morphology better than 13 
14             decent growth, ≅ 9 and 14 
15             large cell bodies + long fragile dendrites 
16             very proliferative 
17             very proliferative 
M2             very proliferative. Cells tripolar. 
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Figure 4.  Cell numbers in culture at day 8.  
Numbers in the bottom row correspond to media conditions in Table 12. 
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Figure 5.  Microscopic photographs of NHEM under various growth conditions 
1.24 x 105 cells were seeded in each well of a 6-well plate at 4 days of incubation 
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Figure 5
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Figure 5 (continued)
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Figure 5 (continued)
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Figure 5 (continued)
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Figure 5 (continued)
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Figure 5 (continued)
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Figure 5 (continued)
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Figure 5 (continued)
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Figure 5 (continued)
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The more growth factors added may increase the cell number or survival, but, it 
was condition #9 with only bFGF and ET-3 that was determined to be the best growth 
condition for viability and morphology. Currently the laboratory continues to extract 
melanocytes by FACS from normal human skin for further study in the defined media 
conditions detailed in this thesis.   Dr. Wang has since shown distinct proliferation using 
time lapse photography, where she was able to make note of dividing cells and keep track 
of the balance between cell death and growth that made simple quantification of these 
cells impossible by methods previously employed.   Dr. Wang is using this defined media 
to grow FACS melanocytes for short and long term culture, analyzing gene expression, 
growth and metabolism under varying times in culture.  Future directions and future 
analyses that would depend on basic information contained within that data-set.   
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Chapter 7.  Extending information to study of melanoma  
Theory and aims 
Malignant melanoma is a potentially life-threatening tumor whose incidence is 
increasing worldwide because of increasing exposure to solar ultraviolet radiation.  It is 
extremely resistant to chemotherapy and has a dismal prognosis once it has spread to 
lymph nodes or beyond.  Many experimental protocols take an immunologic approach, 
trying to stimulate cytotoxic T cells to destroy the tumor.  These strategies, although not 
yet effective, have the advantage of narrowly targeting tumor antigens in order to avoid 
excessive toxicity to other organs.  Melanoma is a particularly good system for 
immunologic therapy since it expresses differentiation antigens restricted to the 
melanocyte lineage.  These proteins are involved in the synthesis and transport of the 
pigment melanin.  However, advanced melanomas often become amelanotic as they 
dedifferentiate.  As tumors downregulate antigen expression they may no longer be 
responsive to targeted therapy.  To this end, we analyzed several cell lines that were 
derived from metastatic melanoma.  We expected them to have variant expression from 
normal melanocytes; but, what was shown was that they actually clustered much closer to 
the in vitro primary PromoCell NHEM.  As shown in the Principal components (PCA) 
plot in figure 6, and the heatmap in figure 7, the melanocytes isolated from “in vivo” skin 
by FACS are the most variant from both of the in vitro NHEM and the samples collected 
from melanoma cell lines at Charité.  The difference is so great that one would almost 
look to the long term in vitro cultured melanocytes as a model for secondary site 
malignancy and not as the “norm”. 
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Figure 6.  Melanoma cell lines cluster with NHEM, not “in vivo” FACS melanocytes.  
The x-axis accounts for 67% of the variation amongst the samples, while the y-axis 17% 
so, the clustering of the principal components of melanoma cell lines with the 
melanocytes in vitro on PC1 relative to the in vivo melanocytes was unexpected. 
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Figure 7.  Heatmap with a cut-off of fold change greater than 4 and p value of 0.01 
Unsupervised hierarquical clustering (Euclidian distance) FACS v Melanoma v in vitro 
again showed clustering of NHEM with melanoma cell lines, both grown in vitro.    
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Figure 8.  Venn diagram representing overlap of variation in gene expression. 
Number of genes differentially up- (in black) or down-regulated (in tan) are depicted in 
each circle, as well as those whose relative expression is shared in common between in 
vitro and FACS melanocytes as compared to the melanoma cell lines in vitro. 
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The difference in gene expression was not very great between NHEM and 
melanoma cell lines, represented in scale as compared to the difference in gene 
expression between FACS melanocytes and melanoma cell lines in the Venn diagram in 
Figure 8.  In comparing the two in vitro groups: NHEM to melanoma, there are not that 
many differentially expressed genes, especially when you take into consideration the 
number of differentially expressed genes from the melanoma cell lines and the FACS 
derived melanocytes.  This data shows the importance of the focus on melanocytes in 
vitro and how they are equivalent to melanoma.  Figure 9 on the following page depicts 
the top 20 differentially expressed genes from each comparison (FAC v. in vitro, in vitro 
v. melanoma cell lines, melanoma cell lines v FACS) that takes a closer look at the genes 
that are highly expressed in vitro NHEM, FACS melanocytes and melanoma cell lines. 
(Melanoma cell line n= 7, FACS n= 10, NHEM n= 12.)  This type of comparison is 
flawed however, by the artifacts produced in culture as well as those of FACS 
methodology.  Some of the genes up-regulated in FACS only are keratinocyte 
contaminants (e.g. KRT6B.)  IL-8 and IL-1B are both up-regulated, while c-kit is down-
regulated in melanoma cell lines.  Further analysis of a greater number of melanoma cell 
lines along with primary and metastatic melanomas needs to be done in this manner to 
determine the genomic phenotype that distinguishes malignant melanoma. 
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Figure 9.  Heatmap of top 20 genes differentially expressed from each type of 
melanocyte compared. Melanoma cell line (n= 7) FACS (n= 10) NHEM (n= 12) 
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Chapter 8.  Discussion 
 
Though culture models of primary cells are not entirely accurate for in vivo 
comparison, there are still many cell specific genes.  To this end primary cell culture of 
epidermal and dermal components were analyzed for unique genes that could then be 
used to analyze complex tissue samples and derive the cellular components.  As we move 
forward into the era of molecular diagnosis, however, it is important to establish a more 
accurate genomic profile of “normal” before pathology can be examined. Therefore, 
diseased skin can be assessed for the purpose of understanding the underlying molecular 
problem so that treatment can be improved upon, handling disease with more appropriate 
treatments and perhaps even by rational chemotherapy in drug development. 
We hypothesize that melanoma, like other cancers, is based on a progression of 
normal cells to dysplastic cells then to neoplastic cells, acquiring additional changes that 
eventually lead to the ability to invade into the dermis and metastasize distantly.  Under a 
Rockefeller IRB protocol we will be studying progression of melanocytes at each of the 
different stages from normal “resting” to transition states to benign proliferations (e.g. 
nevi) to dysplastic states (dysplastic nevi) to melanoma.   
The laboratory will continue to define the properties and molecules that 
distinguish melanocytes from other cell types and to understand the process by which 
normal melanocytes are converted to neoplastic melanocytes and, in particular, acquire 
cellular characteristics that permit them to invade into dermals tissues (vertical growth 
phase) and further metastasize.  Of particular importance is determining the fundamental 
proliferative factors that regulate growth of normal melanocytes, and to establish the 
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extent to which melanoma cells are dependent on these factors for survival and growth.  
Further LCM on pigmented lesions will focus on pathology by focal selection of 
melanocytes from different parts of dysplastic nevi to examine step by step changes in 
gene expression. 
We believe that future strategies for treatment of melanoma will be based on 
either boosting anti-tumour immunity or specific disruption of signaling pathways upon 
which the malignancies depend.  The first approach could use either immunization with 
defined antigens associated with melanoma, melanogenesis etc., or by ex vivo expansion 
of lymphocytes isolated from melanoma patients.  The information on proteins expressed 
in melanocytes at different growth stages could be important for the identification of 
melanocyte-specific proteins that are not part of the recognized pigmentation pathway.  
The second approach is also directly related to the studies that began in this thesis.  The 
principle would be rational chemotherapy based on the identification of key growth, 
differentiation, migration and cell survival pathways that are traceable to specific 
molecules and genomic programs within normal or malignant cells.  The most notable 
example of targeted treatment is PLX4032 which inhibits the elevated kinase activity in 
the RAS-RAF-MEK-ERK pathway created by the B-RAFV600E mutation, present in  
approximately 50% of malignant melanoma (MM) [99].  This drug unfortunately has not 
been shown to increase life expectancy despite clinical benefits in morbidity and visible 
regression of metastases [100].  Other drugs need to be formulated that can act 
synergistically to attack the cancer in a “cocktail” format, as well as the other half of the 
MM population which does not have this specific mutation.   Hence, the pursuit of 
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genomic information to find common growth-regulatory pathway for normal and 
malignant melanocytes needs to be continued.    
In addition, our FACS experiments yielded some very interesting results.  Though 
initially intended to isolate melanocytes for study, the population of keratinocytes also 
revealed novel gene expression potential.  The transcriptome analysis of keratinocytes 
after they had been enzymatically separated from the epidermis revealed many 
similarities to published gene expression during early would healing.  This data indicated 
a plasticity inherent to the keratinocyte previously unreported.  
In summary, in vitro cultures are useful models; but, it is important to recognize 
that they cannot be relied upon for translational research in dermatology because of the 
growth inducing conditions that are so altered from in vivo as to generate gene expression 
profiles which resemble pathologic phenotypes.  These data sets should serve as a 
baseline for future analysis of malignant epidermal states on the transcriptional level. 
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